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 Introduction 
 
1.1 Lung anatomy and respiratory system 
The lungs are the main organs of the respiratory system in humans as well as many other 
animals and are crucial for gas exchange. In humans, the right lung consists of three, 
while the left lung consists of two major lobes because of the asymmetrical placement 
of the heart 1, 2. The lung lies along the upper and lower respiratory tract. The upper 
respiratory tract consists of nose, nasal cavity, sinuses, and pharynx3, while the lower 
respiratory tract consists of trachea, main bronchus, lobar bronchus, segmental 
bronchus, subsegmental bronchus, conducting bronchiole, terminal bronchiole, 
respiratory bronchiole, alveolar duct, alveolar sac and alveolus4. Human and other 
mammals are critically dependent on gas exchange, which takes place in the alveoli. 
They need oxygen (O2) for energy production and have to dismiss the produced carbon 
dioxide (CO2). O2 is required for a metabolic process called cellular respiration, which 
takes place in the mitochondria. Cellular respiration converts biochemical energy from 
nutrients into adenosine triphosphate (ATP)5. Those steps involve an electron transfer 
to O2
5
. There are two types of cellular respiration, aerobic and anaerobic respiration. 
Aerobic respiration requires O2, however when O2 is limited , anaerobic respiration is 
used for survival6. Aerobic respiration makes total 30-32 ATP while anaerobic 
respiration 2 ATP. ATP has a role in providing energy to cells, regulating biochemical 
processes, driving active transport of macromolecules (proteins and lipids) into and out 
of the cell, cell signaling and muscle contraction7. In this regard, the respiratory system 
has a critical function in keeping the organism alive5. 
When atmospheric air has been brought to the surface of the lungs, O2 will start moving 
from the air space (alveoli) into the blood (alveolar capillaries). Oxygenated blood is 
then pumped via the left ventricle into the systemic circulation, delivering O2 to the 
body´s cells. CO2 moves the reverse direction
5. CO2 is produced during cellular 
respiration. It moves out from the cells, enters the bloodstream, moves back to the lungs, 
and is then expired out of the body during exhalation8. Both O2 and CO2 move passively 
via diffusion. Diffusion describes the movement of molecules from a higher to a lower 
concentration9. If there is an increase in the surface area of the lung for gas exchange, 
the O2 diffusion rate increases
5. In the lung, a partial pressure gradient for O2 and CO2 
exists. Since the partial pressure of O2 (PO2) in the atmosphere is greater than the PO2 
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of the blood, the net diffusion of O2 is always from the atmosphere to the blood and for 
CO2 vice versa
9. Next to the surface area size, the thickness of the diffusion barrier 
affects the diffusion rate5. An increase in the alveolar-capillary membrane thickness, 
leads to an attenuated diffusion5. Thus, an optimal respiratory system should have the 
following main features:  
1) A short distance for O2 and CO2 diffusion,  
2) A large surface area for gas exchange  
3) A system that maximizes the partial pressure gradient for O2 and CO2 and avoids 
edema formation5.  
Pulmonary edema is characterized by an abnormal accumulation of fluid in the lung 
impairing gas exchange10, due to an increase in diffusion distance. Since humans have 
high metabolic rates and high requirements for O2, the human respiratory system is 
associated with those main features for maximizing the rate of O2 uptake from the 
atmosphere5. The human respiratory system has a large surface area for gas exchange 
(100m²-145 m2) and an excessively thin but robust barrier (0.2 µm) for gas diffusion5, 
11. 
The respiratory system, which is critically involved in gas exchange, closely works with 
the circulatory system. The blood circulatory system, also called cardiovascular system, 
contains the heart and a network of blood vessels, delivering nutrients and O2 via the 
blood stream to all body´s cells12. Arteries carry the blood away from the heart, whereas 
veins carry the blood back to the heart12. The system of blood vessels has a tree-like 
structure. The main artery (aorta) branches into large arteries, smaller vessels, a 
capillary network and finally to a network of tiny vessels12. Pulmonary artery and 
bronchus lie next to each other, keeping diffusion distance as short as possible, ensuring 
optimal blood oxygenation under physiological conditions12.  
However, besides the structure of the air-blood barrier and the close proximity of 
bronchus and artery, there is a physiological phenomenon called hypoxic pulmonary 
vasoconstriction (HPV), increasing the efficiency of gas exchange.   
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1.2 Hypoxic pulmonary vasoconstriction 
Hypoxic pulmonary vasoconstriction (HPV) is a vascular feedback control mechanism 
in the lung, which was first described by von Euler and Liljestrand in 194613. In this 
mechanism, a drop in alveolar O2 concentration (hypoxia) causes a constriction of small 
pulmonary vessels, shifting blood away from poorly ventilated (hypoxic) areas into 
better ventilated (normoxic) areas of the lung, ensuring optimal blood oxygenation 
(Figure 1)14. The effect of hypoxia differs in the pulmonary and systemic circulation, 
which typically vasodilates in response to hypoxia15. In the lung, acute, regional 
hypoxia and HPV occurring within seconds to minutes is beneficial, matching perfusion 
of the lung to ventilation. However, global hypoxia and thus generalized HPV due to 
chronic hypoxia, which occurs at high altitude or during respiratory diseases, is 
detrimental16. Generalized HPV leads to a global increase in pulmonary vascular 
resistance (PVR) and mean pulmonary arterial pressure (mPAP)17. Moreover, under 
generalized hypoxia, vasoconstriction is fixed by pulmonary vascular remodeling 
leading to PH. In addition to vessel constriction, pulmonary vascular remodeling causes 
vessel lumen obliteration and vessel wall thickening, leading to insufficient oxygenation 
of arterial blood and poor oxygen supply of the body17. The condition of chronic 
elevated mPAP within the pulmonary arteries is known as pulmonary hypertension 
(PH)17. 
 
 
 
 
 
 
Optimization of gas exchange by matching perfusion to ventilation. In a healthy individual, 
blood flow is directed to the areas of the lung that are well ventilated and oxygenated (O2) 
(depicted by large blue circles). Here, an optimal gas exchange and oxygenation of the blood 
(shown in red) is ensured. A very small proportion of the blood reaches areas that are badly 
ventilated and oxygenated (smaller and medium blue circles). In individuals with lung diseases, 
the mechanism of hypoxic pulmonary vasoconstriction is disturbed, causing perfusion of not or 
poorly ventilated areas of the lung and thus leads to a reduced/decreased oxygenation of the 
blood (shown in blue/purple). Blue arrows show the constriction of pulmonary arteries, black 
arrows show the direction of blood flow. The big circles symbolize a high, small a low pO218. 
(Figure is reproduced with permission of the © ERS 2019). 
Figure 1: Hypoxic pulmonary vasoconstriction 
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1.3 Pulmonary hypertension 
Pulmonary hypertension (PH) is a severe disease, causing high mortality19. The 
estimated prevalence of PH is about 15 cases per million patients20. PH is a 
pathophysiological condition defined by an increase in the mPAP of ≥ 25 mmHg at rest, 
accompanied by right heart hypertrophy and eventually right heart failure21, 22. 
Early symptoms of PH include shortness of breath during routine activity, chest pain, 
fatigue, racing heartbeat, decreased appetite and pain in the upper right side of the 
abdomen. Later symptoms include feeling light-headed especially during physical 
activity, fainting, bluish lips or skin and swelling in the ankles or legs23. Factors causing 
PH are: drugs and chemicals, diseases (chronic obstructive lung disease (COPD), 
scleroderma, human immunodeficiency virus (HIV), liver cirrhosis, etcetera), 
phenotype (age, gender), mutations (bone morphogenic protein receptor 2, BMPR2), 
single nucleotide polymorphisms, possible epigenetic inheritance, environmental 
triggers, chronic hypoxia, vasoconstrictor/vasodilator and/or growth factor imbalance22, 
24.  
The diagnosis of PH needs a wide evaluation such as, history of the patient, physical 
examination, laboratory tests which include biomarker testing such as brain natriuretic 
peptide and N-terminal pro-brain natriuretic peptide, pulmonary function testing, 
echocardiography, cardiac catheterization, connective tissue disease serology and some 
tests to exclude chronic thromboembolic disease21, 25. By pulmonary function testing, 
normal lung volumes or a mild restriction can be seen26. Echocardiography, which is a 
sonogram of heart, is mostly used as a first diagnostic test to check the possibility of 
PH27. However, if diagnostic evaluation suggests PH, right heart catheterization will be 
used for confirmation and determination of the severity of PH25. This helps to exclude 
left-sided heart disease25. Lung scintigraphy, computed tomography, cardiac magnetic 
resonance imaging, positron emission tomography scanning and exercise testing are 
used as well28. To see the enlarged central pulmonary arteries and right heart dilation, 
chest radiographs are performed. Electrocardiogram, which records the electrical 
activity of heart, can show right axis deviation and RV hypertrophy26. 
PH is associated with a broad spectrum of histological patterns and abnormalities and 
occurs in a variety of clinical situations22, 29. Since it has such a diversity, a classification  
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system for PH has been developed and recently modified to organize the diseases into 
categories based on common clinical parameters, potential etiologic mechanisms and 
responses to treatment30. 
The clinical classification of PH was first proposed in 1998, during the 2nd World 
Symposium on Pulmonary Hypertension held in Evian, France31 and modified in 2003 
during the 3rd Symposium on Pulmonary Hypertension in Venice29. In the 4rd 
Symposium on Pulmonary Hypertension in Dana Point, 2008, PH was divided in five 
groups32. Group 1 is pulmonary arterial hypertension (PAH), group 2 is PH associated 
with left heart disease, group 3 is PH associated with lung diseases and/or hypoxemia, 
group 4 is PH due to chronic thrombotic and/or embolic disease and category 5 is PH 
with unclear multifactorial mechanisms. Modifications and updates were proposed in 
the 6th World Symposium on Pulmonary Hypertension held in Nice, 2018 (19, 33; Table 
1). Two subgroups “pulmonary arterial hypertension (PAH) long-term responders to 
calcium channel blockers”, due to the specific prognostic and management of these 
patients, and “PAH with overt features of venous/capillaries (pulmonary veno-occlusive 
disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence 
suggesting a continuum between arterial, capillary and vein involvement in PAH were 
added in group 133. 
Table 1: Clinical classification of PH according to the 6th World Symposium in Nice, 
France (Modified from Simonneau 201833) 
1. Pulmonary Arterial Hypertension (PAH) 
 1.1 Idiopathic PAH 
  1.2 Heritable PAH 
   1.2.1 BMPR2 
   1.2.2 ALK-1, ENG, SMAD9, CAV-1, KCNK3 
   1.2.3 Unknown 
  1.3 Drug or toxin induced 
  1.4 Associated with: 
   1.4.1 Connective tissue diseases 
   1.4.2 HIV infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart disease 
   1.4.5 Schistosomiasis 
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1.5 Long-term responders to calcium channel blockers 
1.6 With overt features of venous/capillaries  
1.7 Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
 2.1 Due to heart failure with preserved LVEF 
  2.2 Due to heart failure with reduced LVEF 
  2.3 Valvular heart disease 
 2.4 Congenital/acquired cardiovascular conditions leading to post-capillary     
            PH 
3. Pulmonary hypertension due to lung disease and/or hypoxia 
 3.1 Obstructive pulmonary disease  
 3.2 Restrictive lung disease  
  3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
  3.4 Hypoxia without lung disease 
  3.5 Developmental lung disorders 
4. Pulmonary hypertension due to pulmonary artery obstructions 
4.1 Chronic thromboembolic pulmonary hypertension (CTEPH) 
4.2 Other pulmonary artery obstructions 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
  5.1 Hematologic disorders 
  5.2 Systemic disorders 
  5.3 Others 
  5.4 Complex congenital heart disease 
 
BMPR2: bone morphogenetic protein receptor, type 2, ALK1: activin receptor-like kinase-1, 
HIV: human immunodeficiency virus. CAV-1:  caveolin-1, ENG: endoglin, KCNK3: potassium 
channel subfamily K member 3; LVEF: left ventricular ejection fraction; SMAD9: mothers 
against decapentaplegic 9. 
 
 Group 1 
After the 2nd World Symposium in 1998, different subcategories of Group 1 (PAH) 
have markedly developed in 2013 and additional modifications were made in the Nice 
classification. All subcategories have similar pathological abnormalities, primarily in 
the small pulmonary arterioles19. The subgroups include: 
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Idiopathic PAH  
Idiopathic PAH is a heterogeneous group, which includes idiopathic forms of the 
disease, known as idiopathic PAH (IPAH)22. In IPAH neither a family history of PAH, 
nor an identified risk factor, is known22. 
Heritable PAH 
In heritable PAH, mutations of the bone morphogenetic protein receptor type 2 
(BMPR2), a member of the tumor growth factor (TGF)-β super family, can be identified 
in 80% of the families. More rarely, mutations in other genes belonging to the TGF-β 
super family, which are activin-like receptor kinase-1 (ALK1)34, endoglin (ENG)35, and 
mothers against decapentaplegic 9 (Smad 9) can be identified in 5% of the patients 36. 
Recently, two new gene mutations have been identified, occurring in caveolin-1 
(CAV1)37 and KCNK3, a gene encoding the outwardly rectifying potassium channel 
super family K member 338. 
Drug- and Toxin-Induced Pulmonary Hypertension 
Classic drugs causing PAH include anorexigens, aminorex and fenfluramine 
derivatives, and toxic rapeseed oil39. 
PAH Associated With Connective Tissue Diseases 
The rate of prevalence of PAH in systemic sclerosis patients is between 7% and 12% 
40,41. Most of the long-term studies showed that the outcome of patients with PAH 
associated with systemic sclerosis is markedly worse than that of patients with IPAH, 
despite the use of modern therapies42. 
PAH Associated With HIV Infection 
The prevalence of PH associated with human immunodeficiency virus (HIV) infection 
has been estimated to be 0.5%43. In the early 1990s, the development of specific PAH 
drugs and highly active antiretroviral therapies were extremely poor as well as, the 
prognosis for HIV-PAH. The mortality rate in a year was 50%44.
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PAH Associated With Portal Hypertension 
Portopulmonary hypertension (POPH) means the development of PAH in association 
with elevated pressure in the portal circulation45, 46. Some of the hemodynamic studies 
revealed that, 2% to 6% of patients with portal hypertension have PH47, 48. 
PAH Associated With Congenital Heart Disease in Adults 
Untreated patients with congenital heart disease (CHD), in particular those with relevant 
systemic-to-pulmonary shunts, will develop PAH49. 
PAH Associated With Schistosomiasis 
In 2008, schistosomiasis-associated PAH (Sch-PAH) was included in Group 1. Today, 
Sch-PAH is potentially the most prevalent cause of PAH worldwide19. 
PAH long-term responders to calcium channel blockers 
In 1992, patients with an acute vasodilator response to calcium channel blockers had 
effectively improved survival when treated with long-term calcium channel blockers33. 
In 2005, 6.8% of patients had a long-term clinical and hemodynamic improvement in 
using calcium channel blockers33. Long-term response to calcium channel blockers is 
characterized by clinical improvement (New York Heart Association Functional Class 
I or II) and sustained hemodynamic improvement after at least 1 year, only using 
calcium channel blockers33.  
PAH with overt features of venous/capillaries  
Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis 
(PCH) do not share common conditions with PH, but they have been categorized as 
reasons of PH32. As PVOD and PCH have similar clinical presentations and pathologic 
features, e.g. pulmonary parenchyma changes, these disorders are combined in one 
subgroup in the PH classification system22. 
Persistent pulmonary hypertension of the newborn 
Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome defined by 
sustained elevation of pulmonary vascular resistance (PVR) and is often related with 
normal or low systemic vascular resistance (SVR)50. 
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 Group 2 
PH due to left heart disease belongs to group II and it is the most common cause of 
PH51. Left-sided ventricular or valvular diseases may elevate left atrial pressure, with 
passive backward transmission of the pressure that leads to elevation of PAP30. 
 Group 3 
In Group III (PH due to lung diseases and/or hypoxia), the main cause of PH is alveolar 
hypoxia22. Hypoxia in the lung can occur due to impaired control of breathing, residence 
at high altitude or lung diseases22. Triggers are chronic obstructive pulmonary disease 
(COPD), obstructive sleep apnea (OSA), interstitial lung disease (ILD), alveolar 
hypoventilation disorders, developmental lung abnormalities and chronic exposure to 
high altitude52. Elevation of pulmonary vascular resistance, inflammation of lung tissue 
and airways, fibrotic lung changes, hypoxic vasoconstriction are the main pathological 
features found in this group53. 
 
 Group 4 
Group 4 (chronic thromboembolic pulmonary hypertension) is characterized by 
occlusion of pulmonary arteries which increase PVR and mPAP54. Severe CTEPH can 
lead to right heart failure due to progressive right ventricular dysfunction54. 
 
 Group 5 
Group 5 contains several forms of PH with unclear multifactorial mechanisms22. The 
first subgroup contains several hematologic disorders 22, the second subgroup comprises 
systemic disorders, which are associated with an increased risk of developing PH55. The 
third subgroup includes metabolic disorders22 and the fourth subgroup contains a 
number of miscellaneous conditions such as tumor growth in the central pulmonary 
arteries56. The present thesis mainly deals with PH group one and three, thus in the 
following paragraphs focuses on pulmonary vascular remodeling in these two groups.
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1.4 Pulmonary vascular remodeling 
PH is characterized by pulmonary vascular remodeling, affecting all three layers of the 
blood vessel wall57. Each layer consists of a special cell type. The adventitia consists of 
fibroblasts, the media of pulmonary arterial smooth muscle cells (PASMC) and the 
intima of endothelial cells, which face the blood. Hypertrophy (cell growth) and/or 
hyperplasia (proliferation) of those cell types finally leads to lumen occlusion58. 
Stimuli inducing pulmonary vascular remodeling can be mechanical stretch and shear 
stress (physical stimuli) and/or hypoxia, vasoconstrictor/vasodilator and growth factor 
imbalance (chemical stimuli)58. 
In the adventitia, fibroblasts are activated by a variety of potentially injurious stimuli59, 
leading to increased cell proliferation, expression of contractile and extracellular matrix 
(ECM) proteins and increased secretion of chemokines, cytokines, and 
growth/angiogenic factors59, stimulating PASMC proliferation59. Moreover, hyper-
proliferative fibroblasts can differentiate in SMC, migrating in the media layer59. 
However, media hypertrophy is suggested as the main pathological hallmark of PH60. It 
takes place consistently in arteries, at all levels of the pulmonary arterial tree, and less 
constantly in veins61. Especially in distal pulmonary arteries the abnormal 
muscularization and thus the vessel lumen occlusion is of major importance, since those 
arteries are normally non-muscularized and mainly determine the pulmonary vascular 
resistance (PVR)62. The de-novo muscularization is caused by migration of PASMC 
from proximal to distal and/or by differentiation of pericytes into PASMC that 
subsequently proliferate (Figure 2)62. 
In addition to adventitial and medial changes, endothelial dysfunction contributes to 
pulmonary vascular remodeling. Under physiological conditions endothelium regulates 
vascular tone, production of growth factors, homeostasis (coagulation) and barrier 
function63. However, under pathophysiological conditions, impaired vasoconstriction, 
aberrant endothelial-mesenchymal transition and altered production of endothelial 
vasoactive mediators (nitric oxide (NO), prostacyclin, endothelin-1) and growth factors 
vascular endotheial growth factor (VEGF), platelet-derived growth factor (PDGF) 
occurs64. In addition, hyper-proliferation of endothelial cells leads to plexiform lesion 
formation63. Plexiform lesions are most abundant in small pulmonary artery branches, 
immediately after their origin from a parent artery65. They consist of proliferating 
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myofibroblasts, endothelial and/or fibrillary cells, embedded in an ECM66-68. Moreover, 
encroachment of myofibroblasts and deposition of ECM proteins leads to neo-intima 
formation69 (Figure 2) which is a characteristic response of arteries to several forms of 
injury70. The neo-intima is located between the endothelium and the internal elastic 
lamina70. Besides media hypertrophy, a rise in neo-intima increases PVR64. The initial 
stimulus or injury causing endothelial hyper-proliferation is unknown, but may include 
hypoxia, shear stress, reactive oxygen species, inflammation, or response to drugs or 
toxins on a background of genetic susceptibility63, 71. Moreover, apoptosis of endothelial 
cells (EC) and/or pericytes could lead to the loss of small precapillary arteries72. 
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Pulmonary vascular remodeling involves structural changes in the normal architecture of 
pulmonary arteries, including dysregulated proliferation, migration and apoptosis of pulmonary 
arterial smooth muscle cells (PASMC), fibroblasts and endothelial cells and deposition of 
extracellular matrix proteins. Due to PASMC dysregulation media hypertrophy (ii) and 
abnormal muscularization of previous non-muscularized distal pulmonary arteries occurs (i), 
leading to narrowing and lumen occlusion. In addition, in severe PH forms, vessel loss (iii), 
neo-intima (iv), and plexiform lesion (v) formation takes place69, 72. (Confirmation number of 
figure:1177972569). 
 
Next to vascular cells, ECM structure proteins (collagen, elastin, fibronectin, laminin, 
etc.), providing structural support of surrounding cells, contribute to vessel wall 
thickening and lumen occlusion61. The ECM has a role in determining the physical 
properties of tissues such as mechanical stability, stiffness, porosity, insolubility73 and 
characteristics of the cells within them74. Several studies showed that modifications in 
the composition of ECM lead to the onset and progression of vascular lesions75. Besides 
structure proteins, matricellular proteins are located in the ECM. They do not participate 
directly in the organization or physical properties of structures75. However, they possess 
regulatory cell functions such as angiogenesis, adhesion, migration and proliferation76-
78. They are able to modulate cell-matrix interactions and they possess binding sites for 
many cell surface receptors, growth factor receptors and ECM structure proteins79. In 
this regard, matricellular proteins are expressed at high levels during development and 
responses to injury. The original group of matricellular proteins are thrombospondin-1 
(TSP1), SPARC (secreted protein, acidic and rich in cysteine), tenascin-C, osteopontin 
(OPN) and tenascin X76-78.  
The mitogen transforming growth factor β (TGF-β), among other functions, is a potent 
modulator of ECM synthesis. It stimulates matrix synthesis in wounds and remodeling 
processes80. Other growth factors involved in dysregulation of cellular functions in PH 
are PDGF, VEGF, epidermal growth factor (EGF) and basic fibroblast growth factor 
(bFGF). They are involved in the abnormal proliferation and migration of vascular 
cells81-85. In this regard, it was shown that VEGF is highly expressed in EC of plexiform 
lesions in severe PAH86. PDGF acts as a potent mitogen and chemoattractant for SMC82. 
Both, PDGF and bFGF induce SMC and fibroblast proliferation and migration and thus 
work as key mediators in the progression of PH87. EGF is involved in a tenascin 
dependent SMC proliferation75. Studies revealed the colocalization of EGF with 
tenascin in PH lesions, suggesting a direct role in disease progression87. 
Figure 2: Pulmonary vascular remodeling. 
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Beside of growth factors there are also transcription factors (TFs) which are implicated 
in the pathogenesis of PH88. TFs are sequence-specific DNA-binding proteins that 
control the process of transcription88. Some of the TFs in PH are forkhead box O1 
(FOXO1), krüppel-like factor 4 (KLF4), peroxisome proliferator–activated receptor γ 
(PPARG1), snail family zinc finger 2 (SLUG), signal transducers and activators of 
transcription 3 (STAT3), nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 (NFATc2), hypoxia-inducible factor 1α (HIF1α) and hypoxia-inducible 
factor 2α (HIF2α)88. HIFs are main regulators of the molecular response to hypoxia and 
strongly implicated in the pathogenesis of PH by targeting genes controlling 
vascularization, cellular proliferation, migration and metabolism89, 90. 
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1.5 Treatment options 
Over the past 20 years, more and more treatment options for PH came up91, however 
PH is still not curable.  
Conventional medical therapies with oral, inhaled and intravenous options are used for 
the treatment for PH. Heart or lung transplant may also be an option depending on the 
severity of PH92. Conventional medical therapies used in PH include: Calcium channel 
blockers, Digoxin, diuretics, oxygen and Warfarin (Coumadin®)92. Calcium channel 
blockers inhibit the calcium influx in cells and thus impair calcium-dependent 
vasoconstriction. They are the first vasodilator agents used in the treatment of PH93. 
However, calcium channel blockers are only appropriate for a small minority of patients, 
demonstrating a favorable response to vasodilator-testing during heart catheterization92. 
Digoxin supports the heart contractility92. Diuretics are used to increase diuresis and 
thereby decreasing blood pressure92. Oxygen therapy helps to improve blood 
oxygenation. Patients generally inhale oxygen by a nasal cannula or a face mask92. 
Warfarin prevents blood clotting and thus thrombus formation92.  
Next to conventional treatment options, oral, inhaled or intravenous medications are 
available. For several years prostacyclin analogues, phosphodiesterase 5 (PDE-5) 
inhibitors and endothelin receptor antagonists were used for treatment of PH94. These 
medications target prostacyclin, endothelin (ET)-1, and nitric oxide (NO) pathways that 
are dysregulated in PH95.  
Prostacyclin initiates vasodilation by cyclic adenosine monophosphate and has both 
anti-proliferative and anti-coagulative effects96. Available prostacyclins are: 
Treprostinil (Orenitram®), Iloprost (Ventavis®), Treprostinil (Tyvaso™ and 
Remodulin®) and Epoprostenol (Flolan® and Veletri®)92.  
ET-1 is an efficient vasoconstrictor, which is produced and secreted by the vascular 
endothelium97. Blockage of ET -1 receptors by Macitentan on PASMC reverses 
pulmonary vasoconstriction98, 99. Next to Macitentan (Opsumit®), Ambrisentan 
(Letairis®) and Bosentan (Tracleer®) are available endothelin receptor antagonists92. 
NO vasodilates the pulmonary arterial circulation by diffusing across the alveolar-
capillary membrane into the pulmonary artery smooth muscle. It activates soluble 
guanylate cyclase and increases the levels of cyclic guanosine 3′5′-monophosphate 
(cGMP)100. 
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PDE 5 inhibitors increase endogenous cGMP levels. Available PDE 5 inhibitors for 
treatment of PH are Sildenafil (Revatio™) and Tadalafil (Adcirca®)92.  
Newer approved drugs are: Riociguat (Adempas®), Treprostinil and Selexipag 
(Uptravi®)91, 101. Riociguat is a soluble guanylate cyclase stimulator, producing cGMP, 
which causes blood vessel relaxation. The pulmonary blood pressure decreases and the 
heart function is improved102-104. The advantages of the new approved drugs are 
delaying the time of clinical worsening94, improving the  6-minute walk distance 
(6MWD), cardiopulmonary hemodynamics105 and exercise capacity94. 
Targeting those pathways improves symptoms, survival and quality of life106. However, 
many of the medications have complex administration regimens and considerations, 
along with significant side effects and monitoring requirements94. 
However, until now there is no drug available which can fully reverse PH, thus research 
is still needed, identifying new pathways and targets91. 
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1.6 Animal models of pulmonary hypertension 
Using animal models of PH is a valuable tool to study the various underlying 
pathobiological mechanisms and to test new treatment strategies107. 
The most commonly used animal models of PH are the chronic hypoxia model in 
different species and the monocrotaline injury model in rats107. Both models are widely 
available, have well-described histopathological characteristics and possess good 
reproducibility107. 
However, nowadays, various additional experimental PH models are available. Those 
models include, physically, chemically and genetically-induced models as well as single 
and multiple stimuli models (Figure 3). Every model has its specific characteristics and 
thus is used to investigate a particular category of human PH.  
 
 
 
 
 
 
 
 
 
 
Physical, chemically-induced, genetic and multiple stimuli models used in PH research108. 
 
Figure 3: List of animal models used in PH research 
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An ideal PH model reflects the key clinical, hemodynamic and histopathological 
features of human PH109. However, until now each models has its limitations. So far, 
there is no perfect and ideal animal model that fully reflects the complex 
pathophysiological changes of human PH30. There are species-specific differences and 
the three critical points of the human disease: obliteration of pulmonary arterioles, non-
reversibility and development of the right ventricle failure (RVF) are not reflected in 
each model108. In this regard, multiple stimuli approaches reflect the human disease 
better than single stimuli approaches110. However, single stimuli approaches are 
suggested to reflect the characteristics of early PH110. 
In the present thesis mice were exposed to chronic hypoxia, thus the following 
paragraphs provides more details about this specific model. 
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1.7 Chronic hypoxia-induced Pulmonary Hypertension  
In a wide variety of animal species, such as mouse, pig, rat, and cattle, normobaric 
(normal pressure but reduced O2 concentration (10% O2, balanced by N2) and hypobaric 
(O2 concentration is constant and pressure is reduced (380mmHg ≈ 5500m)) hypoxia 
are frequently used to induce PH108, 109. As variety of genetically modified mice are 
available, they are a desirable tool for studying chronic hypoxia-induced PH30.  
Pathological findings from animals exposed to chronic hypoxia are muscularization of 
small previous non-muscularized arterioles, increased mPAP and right heart 
hypertrophy30, 109. 
Besides rats, mice are the most commonly used animals in this model30. Both develop 
similar pathological changes following exposure to chronic hypoxia. However, the 
degree of remodeling and hemodynamic changes are more severe in rats108, 109. In 
normoxic mice, RVSP is between 10-20 mmHg, whereas in hypoxic mice it is between 
14-26 mmHg108. Moreover, factor of right ventricular hypertrophy (RVH) (RV/LV+S) 
in normoxic mice is 0.24, while it is 0.32 in hypoxic mice108. In normoxic rats, RVSP 
is 21 mmHg and in hypoxic rats is 47 mmHg111. RVH in normoxic rats is 0.18 and in 
hypoxic rats 0.44112. 
Limitations of the chronic hypoxia-induced animal models are;  
1) The response to hypoxia is variable among animal species and age of animals, 
2) There is a lack of right ventricular failure109  
3) There is no intimal cell proliferation and  
4) There are no complex pulmonary vascular lesions.  
Moreover, when the hypoxic stimulus stops and mice/rats re-oxygenate to room air 
oxygen concentration, chronic hypoxia-induced PH is reversible, a process called 
reverse-remodeling113. The following paragraph deals with this phenomenon.   
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1.8 Reverse remodeling in mice  
In 1960s it was observed that high altitude hypoxia leads to PH in humans114, which can 
be partially reversed after returning to sea level115. In 1971, experimental studies showed 
that exposure of rats to hypobaric pressure (5500m) leads to PH, including right heart 
hypertrophy and muscularization of small pulmonary arteries116. The increase in right 
ventricular weight and muscularization was reversible after 37 days recovery116. 
In 1973, an experiment in rats was conducted, increasing the recovery time after chronic 
hypoxic exposure to 5 weeks. It was found that right ventricular hypertrophy was 
partially reversible. The thickness of the main pulmonary artery and the volume of the 
hypertrophied carotid body decreased117. 
The reversal of right heart hypertrophy and pulmonary artery muscularization after re-
exposure of rats to normoxia was confirmed in 1977118. 
In 2014, reverse remodeling findings in rats were transferred to mice, revealing that 
chronic hypoxia-induced PH is fully reversible upon re-exposure to normoxia. Right 
heart hypertrophy as well as pulmonary vascular remodeling was completely 
reversible113 (Figure 4). 
 
 
 
 
 
 
 
Chronic hypoxic exposure leads to pulmonary vascular remodeling, which is reversible upon 
re-exposure to normoxia A: Adventitia, M: Media, E: Endothelium.  
Figure 4: Reverse remodeling 
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1.9 Aim of the study 
Until now, research in the field of PH concentrates mostly on the onset and development 
of PH. In this study, we focus on mechanisms underlying the reversal of PH. It was 
previously shown that chronic hypoxia-induced vascular remodeling in mice can be 
reversed by re-exposure to normoxia113. In this regard, a microarray analysis from 
murine lung homogenate was performed, screening for potential candidate genes 
contributing to reverse remodeling. S-adenosylmethionine decarboxylase 1 (AMD-1) 
was identified as a novel potential candidate gene. AMD-1 is elevated expressed in 
chronic hypoxic mice and down-regulated following re-oxygenation of mice. 
Furthermore, it is critically involved in dysregulated PASMC proliferation and 
apoptosis. In addition, AMD-1 knockout mice possess less chronic hypoxia-induced PH 
than respective controls113. 
Going beyond this approach, we now wanted to specifically focus on the gene 
expression alterations in the lung vasculature, possibly enhancing the chance to detect 
additional relevant new pathways and targets for pulmonary vascular remodeling. In 
this regard, pulmonary vessels from mice, exposed under normoxia, chronic hypoxia 
and chronic hypoxia with subsequent normoxic exposure for different time points, will 
be laser-microdissected followed by microarray analysis. Expression of identified 
targets will be validated in chronic hypoxic mice, in IPAH patients and on cellular level. 
Moreover, the functional role will be assessed in vitro as well as in vivo by using 
respective knockout mice. 
It is hypothesized that, the microarray technique leads to identification of new candidate 
genes and their relevant signaling pathways underlying pulmonary vascular remodeling 
which will help to identify novel treatment strategies for PH. 
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 Materials and Methods 
 
2.1 Materials 
 
 Equipment 
Catheter - MiniVent type 848  Elektronik-Harvard Apparatus, March,  
Hugo Sachs      Germany 
Cell incubator HERAcell 150  Thermo Scientific, Dreieich, Germany 
Centrifuge Hematocrit 210   Hettich, Tuttlingen, Germany 
Centrifuge Rotanta 460R   Hettich, Tuttlingen, Germany                                                               
CFX Connect™ Real-Time PCR  Biorad, Munich, Germany 
Detection System  
ChemiDocTM Touch Imaging   Biorad, Munich, Germany 
System 
ChemiDocTM XRS+    Biorad, Munich, Germany 
Cooling Plate EG 1150C   Leica Microsystems, Wetzlar, Germany 
Computer Q 550 IW    Leica Microsystems, Wetzlar, Germany 
Digitale Camera DC 300F   Leica Microsystems, Wetzlar, Germany 
GenePix 4100A Scanner   Axon Instruments, Union City, NJ, USA 
Glass plates (1.5 mm)   Biorad, Munich, Germany 
Hematocrit 210 Centrifuge   Hettich, Tuttlingen, Germany 
Heating Block    VWR, Bruchsal, Germany 
Heating Plate Hi 1220   Leica Microsystems, Wetzlar, Germany 
HLC Heating-ThermoMixer DITABIS Digital Biomedical Imaging 
Systems, Pforzheim, Germany 
Homeothermic plate    AD Instruments, Spechbach, Germany 
Homogenizer PRECELLYSR24  PeqLab, Erlangen, Germany 
Hotplate/Stirrer (371)   VWR, Bruchsal, Germany 
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Infinite M200     Tecan, Männedorf, Switzerland 
Laser Microdissection system  Leica Microsystems, Wetzlar, Germany  
LMD 600 
Low Voltage Power Supplies  Biometra, Analytic Jena, Jena, Germany 
Power pack P25T 
Magnet for Tubes   Thermo Fisher Scientifc Inc. Waltham, 
(DynaMagTM-Spin Magnet)   USA 
Micro-tip catheter SPR-671NR  Millar Instruments, Houston, USA 
MiniVent type 845 Hugo Sachs  Elektronik, March-Hugstetten, Germany 
Multimode microplate reader  Tecan, Männedorf, Switzerland 
Infinite 200 PRO  
Multimode microplate reader Spark® Tecan, Männedorf, Switzerland 
NanoDrop (ND-1000)   Kisker-Biotech, Steinfurt, Germany 
Ultrapure Milli-Q®    Millipore, Schwalbach, Germany 
Paraffin cooling station    Leica, Wetzlar, Germany 
Leica EG 1150C  
Paraffin embedding station   Leica, Wetzlar, Germany 
Leica EG 1140H 
PCR Plate sealer PX1   Biorad, Munich, Germany 
PEN membrane slides   Leica Microsystems, Wetzlar, Germany 
pH meter-766 Calimatic   Knick, Berlin, Germany 
Rectal thermometer    Indus Instruments, Houston, TX, USA 
Table Centrifuge Mikro 200R  Hettich, Tuttlingen, Germany 
Thermocycler, Tpersonal   Biometra, Analytic Jena, Jena, Germany 
Thermocycler, T3000   Biometra, Analytic Jena, Jena, Germany 
Tissue Tek     Sakura Finetek, Staufen, Germany 
Ultrapure water-Milli Q®   Millipore, Schwalbach, Germany 
Vortexer MS1 Minishaker   IKA GmbH, Staufen, Germany 
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Waterbath     Memmert, Schwabach, Germany 
 
  Chemicals and consumables 
0,9 % NaCl-Solution    B.Braun, Melsungen, Germany 
Aceton     Sigma-Aldrich, Munich, Germany 
Agarose     Fermentas, St. Leon-Rot, Germany 
Amersham ECL Plus Western Blotting GE Healthcare, Munich, Germany 
Detections System                                                               
Ammonium persulfate (APS)  Promega, Mannheim, Germany 
Ampuwa®     Fresenius Kabi, Bad Homburg, Germany 
Antibody Diluent    Zytomed Systems, Berlin, Germany 
β-Mercaptoethanol    Sigma-Aldrich, Munich, Germany 
Bovines Serum Albumin (BSA)  Sigma-Aldrich, Munich, Germany 
BSA-Solution     Biorad, Munich, Germany 
Cell lysis buffer Cell Signaling Technology, Cambridge, 
UK 
Cpd 22, Calbiochem®   Merck, Darmstadt, Germany 
Deionised Water (dH2O)   Milliporanlage in Laboratory 
Deoxynucleotide (dNTP)   Promega, Mannheim, Germany 
Distilled Water (dH2O, DNAse-/  GibcoTM Invitrogen, Karlsruhe, Germany 
RNAse-free) 
Disodiumhydrogenphosphate (Na2HPO4) Merck, Darmstadt, Germany 
Double distilled Water (ddH2O)  Carl Roth, Karlsruhe, Germany 
Dimethylsulfoxid (DMSO)   Sigma-Aldrich, Munich, Germany 
Ethanol 70 %, 96 % und 100 % Otto Fischer GmbH, Saarbrücken, 
Germany 
Ethanol (pure) for molecular biology Merck, Darmstadt, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Munich, Germany 
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Flexi Buffer     Promega, Mannheim, Germany 
Glycerol     Sigma-Aldrich, Munich, Germany 
Glycin      Carl Roth, Karlsruhe, Germany 
GoTaq polymerase    Promega, Mannheim, Germany 
Hematoxylin     Biocare Medical, Pacheco, CA 
Hydrochloride (HCl)    Carl-Roth, Karlsruhe, Germany 
Hydrogen peroxide (H2O2)   Merck, Darmstadt, Germany 
Isopropylalcohol (2-Propanol)  Merck, Darmstadt, Germany 
Lysis Buffer (9803S)    Cell Signaling Danvers, MA, USA 
Magnesium Chloride (MgCl2)  Promega, Mannheim, Germany 
Monopotassiumdihydrogenphosphate Merck, Darmstadt, Germany 
(KH2PO4) 
Methanol     Sigma-Aldrich, Munich, Germany 
Methyl green Vector Laboratories, Burlingame, CA, 
USA 
Microarray Slides Mouse whole  Agilent Technologies, Palo Alto, CA, USA 
Genome 4x44K 
Paraformaldehyde    Carl Roth, Karlsruhe, Germany 
Phenylmethansulfonylfluorid (PMSF) Sigma-Aldrich, Munich, Germany 
Phenylmethylsulfonyl Fluoride  Pall Corporation, Dreieich, Germany 
(PVDF)-membrane  
Potassiumchloride (KCl)   Merck, Darmstadt, Germany 
Proteinase K NovocastraTM   Leica, Wetzlar, Germany 
Skimmed milk powder   Sigma-Aldrich, Munich, Germany 
Sodiumchloride (NaCl)   Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS)  Promega, Mannheim, Germany 
Sodium hydroxide (NaOH)   Carl Roth, Karlsruhe, Germany 
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Sodium ortho vanadate (Na3VO4)  Sigma-Aldrich, Munich, Germany 
SYBR® Safe     Invitrogen, Karlsruhe, Germany 
SYBR® Safe DNA gel stain   Invitrogen, Karlsruhe, Germany 
T-EDTA Buffer pH 9.0   Zytomed Systems, Berlin, Germany 
Tetramethylethylenediamine   Carl Roth, Karlsruhe, Germany 
(TEMED)      
Tergitol® (NP-40)    Sigma-Aldrich, Munich, Germany 
TRIS Base     Sigma-Aldrich, Munich, Germany 
TRIS-HCl     Sigma-Aldrich, Munich, Germany 
Triton-X     Sigma-Aldrich, Munich, Germany 
Tween® 20     AppliChem, Darmstadt, Germany 
Xylol      Carl Roth, Karlsruhe, Germany 
 
 Cell culture 
Canule 16G, 18 G    BD Microlane, Franklin Lakes, USA 
Cell culture dishes,    Sarstedt, Nümbrecht, Germany 
(35er, 60er) 
Cell culture flasks,    Greiner bio-one, Frickenhausen, Germany  
(T-25, T-75) 
Cell culture plate    Greiner bio-one, Frickenhausen, Germany  
(6, 12, 24, 96 well)  
Cell scrapers     Greiner bio-one, Frickenhausen, Germany 
Cryo Tubes     Sarstedt, Nümbrecht, Germany 
Falcon-Tubes     Greiner bio-one, Frickenhausen, Germany  
Fetal calf serum (FCS)   PAA Laboratories, Cölbe, Germany 
Filtered tips, 10, 100, 1000 µl  Nerbe plus, Winsen, Germany 
Heparin, Heparin-Natrium   Ratiopharm GmbH, Ulm, Germany 
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-5000-ratiopharm®  
Ketaminhydrochlorid 100 mg/mL,  Bela-Pharm, Vechta, Germany 
Ketamin®, 10%ig  
Lipofectamine 2000    Invitrogen, Karlsruhe, Germany 
Medium 199 (M199)    GIBCO Invitrogen, Karlsruhe, Germany 
Micro tube 0.5, 1.5, 2.0 ml   Sarstedt, Nümbrecht, Germany 
Micro tube 0.5, 1.5, 2.0 ml   Sarstedt, Nümbrecht, Germany 
DNA-/DNase-/RNase-/PCR- 
inhibitor free 
Neubauer counting chamber LO Laboroptik GmbH, Bad Homburg, 
Germany 
Opti-MEM Medium    Gibco, Darmstadt, Germany 
PCR Plate 96-Well,    Biorad, Munich, Germany 
MultiplateTM PCR Plates, clear 
Penicilin/Streptomycin (Pen Strep, P/S) Gibco, Life Technologies, Carlsbad, USA 
Phosphate puffered saline (PBS)  PAN Biotech, Aidenbach, Germany 
Pulmonary arterial smooth muscle cells Lonza, Köln, Germany 
(PASMC) 
Serological pipette 5, 10, 25, 50 ml  BD Falcon, Heidelberg, Germany 
Smooth Muscle Cell Basal Medium  PromoCell, Heidelberg, Germany 
Smooth Muscle Cell Growth Medium 2 PromoCell, Heidelberg, Germany 
Smooth Muscle Supplement 2 mix  Promo cell, Heidelberg, Germany 
Sterile filter 0,22 µm    Millipore, Schwalbach, Germany 
Trypsin/EDTA (10x)    PAN-Biotech, Aidenbach, Germany 
Xylazinhydrochlorid, Xylazin® 2%ig  Ceva Tiergesundheit, Düsseldorf, 
Germany 
 
 Ligands and inhibitors 
Epidermal growth factor (EGF, human) Peprotech, Hamburg, Germany 
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Platelet -derived growth factor  Peprotech, Hamburg, Germany 
(PDGF-BB, human)     
Rapamycin     Sigma Aldrich, Munich, Germany 
Transforming growth factor beta 1  Peprotech, Hamburg, Germany 
(TGF-β1, human)     
Vascular endothelial growth factor  Peprotech, Hamburg, Germany 
(VEGF, human)       
Wortmannin     Sigma Aldrich, Munich, Germany 
 
 siRNA 
 
HIF-1α ON-TARGETplus SMARTpool DharmaconThermo Scientific, Schwerte, 
L-004018-00 Germany 
HIF-2α ON-TARGETplus SMARTpool DharmaconThermo Scientific, Schwerte, 
L-004814-00     Germany 
ILK ON-TARGETplus SMARTpool DharmaconThermo Scientific, Schwerte,  
L-004499-00 Germany 
L-004499-00 siRNA Negative Control   Eurogentec Cologne, Germany 
SR-CL000-005 
SPARC ON-TARGETplus SMARTpool DharmaconThermo Scientific, Schwerte, 
L-003710-00     Germany 
 
 
 Markers and enzymes 
GeneRuler™ 100 bp DNA Ladder  Fermentas, St. Leon-Rot, Germany 
GoTaq Polymerase    Promega, Madison, USA 
Precision plus ProteinTM Dual Color  Biorad, Munich, Germany 
Standards 
 
 
 Kits and assays 
AP Polymer System    Zytomed Systems, Berlin, Germany 
BCA assay     Pierce, Rockford, IL, USA 
Cell proliferation ELISA, BrdU  Roche, Mannheim, Germany 
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(colorimetric)  
DAB Peroxidase Substrate Kit Vector Laboratories, Burlingame, CA, 
USA 
Dual-color QuickAmp Kit   Agilent, Palo Alto, CA, USA 
iScript cDNA Synthesis Kit   Biorad, Munich, Germany 
ImmPRESS Anti-Rabbit Ig Polymer Vector Laboratories, Burlingame, CA, 
Detection-Kit     USA 
Mouse-on-mouse HRP-Polymer Kit  Zytomed Systems, Berlin, Germany 
RNeasy®Mini Kit    Qiagen, Hilden, Germany 
RNeasy®Micro Kit    Qiagen, Hilden, Germany 
TGX FastCast Kit (12% gels)  Biorad, Munich, Germany 
VECTOR VIP Peroxidase Substrate Kit Vector Laboratories, Burlingame, CA, 
USA 
VECTOR NovaRED Peroxidase Substrate Vector Laboratories, Burlingame, CA,  
Kit      USA 
Warp Red Chromogen Kit   Biocare Medical, Pacheco, CA, USA 
 
 Antibodies 
2.1.8.1 Primary antibodies 
AKT (#9272S)    Cell Signaling, Danvers, MA, USA 
β-Actin (A228)    Sigma-Aldrich, Munich, Germany 
Cyclin D1     Abcam, Cambridge, UK 
(#ab134175) 
ERK1/2     Cell Signaling, Danvers, MA, USA 
(137F5, #4695S)                               
HIF-1α     Cayman Chemical, Ann Arbor, MI USA 
(#10006421)                                      
HIF-2α     Novus Biologicals, Wiesbaden, Germany 
(#NB100-132) 
ILK (#3862)     Cell Signaling, Danvers, MA, USA 
IgG      Millipore, Schwalbach, Germany 
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phospho-AKT    Cell Signaling, Danvers, MA, USA 
(S473, #9271S)                        
phospho-ERK1/2    Cell Signaling, Danvers, MA, USA 
(T202/Y204, #9101S)         
SPARC     Cell Signaling, Danvers, MA, USA 
(D10F10, #8725s)                               
Von-Willebrand-Factor   Dako, Hamburg, Germany 
(A0082)                      
α-smooth muscle actin   Sigma-Aldrich, Munich, Germany 
(A2547)            
            
2.1.8.2 Secondary antibodies 
Horseradish-peroxidase–labeled  Promega, Mannheim, Germany 
secondary antibodies             
Anti-mouse W4011  
Anti-rabbit W4021  
 
 
 Computer programes 
GraphPad Prism Version 7 GraphPad Software, Inc., La Jolla, CA, 
USA 
Image Lab Version 4.1   Biorad, Munich, Germany 
LabChart 7     AD Instruments, Spechbach, Germany 
PowerLab data acquisition system  AD Instruments, Spechbach, Germany 
(MPVS-Ultra Single Segment  
Foundation System) 
Qwin software    Leica, Wetzlar, Germany 
 
 
 Animals 
C57Bl/6J Charles River Laboratories, Sulzfeld, 
Germany  
Secreted protein acidic and rich in  Jackson Laboratory, Bar Harbor, Maine,  
cysteine knockout mice (SPARC-/-)  USA  
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(JAX stock #003728)    
B6129SF2/J Jackson Laboratory, Bar Harbor, Maine, 
USA 
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2.2 Methods  
 
 Experimental design 
For microarray analysis, adult C57BL/6J mice were exposed to chronic hypoxia (10% 
O2) in a ventilated chamber to induce pulmonary vascular remodeling as previously 
described113. Briefly, animals were age-matched and randomly distributed to groups that 
are either exposed to 21 days to normobaric normoxia [inspiratory O2 fraction (FiO2) 
0.21] or normobaric hypoxia [FiO2 of 0.10] with subsequent re-exposure to normoxia 
for 1, 3, 7 and 14 days.  
For deciphering the role of SPARC in chronic hypoxia-induced PH, B6129SF2/J and 
SPARC-/- mice were obtained from Jackson Laboratory for breeding. Briefly, animals 
were age-matched and randomly distributed to groups that are either exposed to 28 days 
normoxia (21% O2) or 28 days hypoxia (10% O2). 
All animal experiments were approved by the local authorities GI 20/10 22/2000, GI 
20/10 77/2015 (Regierungspraesidium, Giessen, Germany). 
 
 Patient characteristics and measurements 
Tissue samples from human explanted lungs were obtained from 11 donors (mean age 
42 ± 31, 6 female, 5 male) and 14 IPAH patients (mean age 33 ± 28, 9 female, 5 male). 
Lung tissue was either snap-frozen in liquid nitrogen directly after explantation or 
placed in 4% m/v paraformaldehyde within 30 min. after lung explantation. The study 
protocol was approved by the Ethik-Komission des Fachbereichts Medizin (AZ 10/06) 
of the Justus-Liebig-University Giessen, Germany. 
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 Genotyping 
DNA isolation was performed from mouse tail cuts or ear marks. Per sample, 300 µl of 
50 mM NaOH was added, following incubation in an HLC heating thermomixer (95oC, 
800l/min, 15 min.). Afterwards, samples were vortexed for 10 sec. at 595g. After that, 
50 µl 1 M Tris was added and samples were centrifuged for 5 min. at 16089g. 
After the DNA isolation, PCR was performed using GoTaq polymerase. The following 
reaction conditions were used for PCR in the thermocycler T3000: 3 min. at 94°C, (30 
sec. at 94°C, 1 min. at 65°C, 1 min. at 72°C) 35 times 30 sec. at 94°C, 5 min. at 72°C 
and stop at 10°C. The following master mix per sample was prepared and Table 2 shows 
primer sequences used for genotyping. 
 
Ampuwa®    3.80 µl 
FlexiBuffer    3.00 µl 
MgCl2     1.20 µl 
dNTPs     0.30 µl  
Primer 1    1.50 µl  
Primer 2    1.50 µl  
Primer 3    1.50 µl  
GoTaq-Polymerase   0.20 µl 
DNA      2.00  μl 
          15   μl 
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Table 2: Primer sequences for genotyping 
Gene Sequence 
Primer 1 TTCTTCCTTGCAACCCTCTC 
Primer 2 GGGGTTTGCTCGACATTG 
Primer 3 TGTGGAGCTTCCTCTGTCCT 
 
Following PCR, gel electrophoresis was performed to identify the genotype. An agarose 
gel (1.5%) was prepared as described below (Table 3), (Table 4). The gel 
electrophoresis was performed at 400 Volt, 250 mA for 15 min. The gel was visualized 
using a ChemiDocTM XRS+ device. As shown in Figure 5, a double band referred 
heterozygous SPARC, lower single band referred homozygous SPARC-/- and the upper 
single band at the gel referred homozygous SPARC WT. 
 
Table 3: Preparation of Agarose gel for Genotyping 
Reagents Amount 
Agarose 0.75 g 
1x SB Buffer 50 ml 
SYBR® Safe Gel Stain 2 μl 
 
Table 4: Preparation of SB Buffer for Genotyping 
 
 
 
 
 
 
 
 
  
Reagents Amount 
1x SB Buffer 50 ml 20x SB Buffer 
950 ml dH2O 
 
20x SB Buffer 
8 g NaOH 
42 g boric acid 
1000 ml dH2O 
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Figure 5: Gel electrophoresis for genotyping 
Bands referring to heterozygous, KO and WT between the size of 240 to 385 bp.  
 
 Hemodynamic measurements  
Hemodynamic measurements done by Karin Quanz. For hemodynamic measurements, 
normoxic/hypoxic wild-type/SPARC-/- mice were anesthetized with inhaled isoflurane 
in room air supplemented with 100% O2. The mouse was placed supine on a 
homeothermic plate and after tracheotomy connected to a small animal ventilator 
MiniVent type. The body temperature was controlled by a rectal probe connected to the 
control unit and was kept at 37°C during the catheterization. The right external jugular 
vein was catheterized with a SPR-671NR micro-tip catheter and advanced into the right 
ventricle to assess the right ventricular systolic pressure (RVSP). Data were collected 
and analyzed using the PowerLab data acquisition system and LabChart 7 for Windows 
software. After exsanguination, the left lung was fixed for histological investigations in 
3.5% neutral buffered formalin. The right lung was snap-frozen in liquid nitrogen for 
molecular biological investigations. For measuring the right heart hypertrophy, the right 
ventricle (RV) was separated from the left ventricle plus septum (LV+S) and the 
RV/(LV+S) ratio (fulton index) was determined.  
 
 Echocardiography 
Echocardiography was done by Dr. Simone Kraut and performed as previously 
described113. In short, mice were anesthetized with isoflurane gas (3%) and maintained 
with 1.5% isoflurane in room air supplemented with 100% O2. For monitoring heart rate 
(HR), mice were set in a flat position on a heating platform with all legs taped to ECG 
electrodes. A rectal thermometer was used to monitor the body temperature. After 
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shaving, a pre-warmed ultrasound gel was spread over the chest wall for providing a 
coupling medium for the transducer. A Vevo 2100 high-resolution imaging system 
equipped by a 55-MHz transducer (VisualSonics, Toronto, Canada) was used for 
transthoracic echocardiography. Cardiac output (CO) is the volume of blood being 
pumped by the heart, in particular by the left or right ventricle, per unit time119. CO was 
calculated as the product of the velocity-time integral of the pulsed-Doppler tracing in 
the LV outflow tract, the cross-sectional area of the LV outflow tract, and the heart 
rate113. Cardiac index (CI) relates heart performance to the size of the individual.  CI 
was calculated by dividing CO by body weight. Following, B-mode derived right 
ventricular internal diameter (RVID) was measured. Right ventricular wall thickness 
(RVWT) was measured in AM-mode. AM-mode represents images in higher 
magnification than in the commonly used M-mode, allowing a more precise analysis.  
 
 Paraffin embedding, immunohistochemical staining and microscopy 
Lungs were flushed with saline, using a vascular pressure of 22 cm H2O and a tracheal 
pressure of 12 cm H2O. A catheter from MiniVent type 848 into trachea and one saline 
catheter into pulmonary artery was inserted. Stroke volume of MiniVent was adjusted 
to 150-200 µl. Next, a catheter was put into pulmonary artery and afterwards, organs 
were harvested for molecular biological experiments. Finally, MiniVent pressure was 
decreased to <100 µl stroke volume and left lung was harvested and fixed by immersion 
in a 3.5% paraformaldehyde solution113. 
The left lungs were dissected in tissue blocks for paraffin embedding. Three μm sections 
of paraffin embedded lungs were used for the investigations. For assessing the degree 
of pulmonary vessel muscularization, lung sections were stained with antibodies against 
α-smooth muscle actin (α-sma) and von Willebrand factor (vWF) as described in the 
Table 5. As negative control, an isotype (IgG) control staining was performed. 
 
Table 5: Protocol for double immunostaining against α-sma and vWF 
Incubation 
time 
Reagents Comments 
60 min. by 58oC  
10 min. Xylol  
10 min. Xylol  
10 min. Xylol  
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5 min. Ethanol absolute 99.6%  
5 min. Ethanol absolute 99.6%  
5 min. Ethanol 96%  
5 min. Ethanol 70%  
20 min. H2O2- methanol mixture 3% 180 ml methanol + 20 ml 
H2O2 30% 
2x5 min. Aqua dest. (Millipore) Shake 
2x5 min. 1x-PBS Shake 
30 min. Proteinase K 1,6 ml diluent + 1 drop of 
Proteinase K (40 x) 
3x5 min. 1x-PBS Shake 
20 min. 10 % BSA  
3x5 min. 1x-PBS Shake 
30 min. Rodent Block M 
(Mouse on Mouse HRP Polymer) 
Zytomed Systems Blue 
3x5 min. 1x-PBS Shake 
30 min. Primary antibody (α-actin) 1:700 with antibody diluent 
200 µl/slide 
4x5 min. 1x-PBS Shake 
20 min. Mouse on Mouse HRP Polymer Zytomed systems yellow 
3x5 min. 1x-PBS Shake 
 
 
1 to 4 min. 
 
 
Vector Vip. Substrat Kit 
5 ml PBS + 3 drops from 
Reagent 1 
+ 3 drops from Reagent 2 
+ 3 drops from Reagent 3 
+ 3 drops from H2O2 
5 min.  H2O Shake 
2x5 min. 1x-PBS Shake 
20 min. 10 % BSA  
3x5 min. 1x-PBS Shake 
20 min. Serum Block 1 2.5 % Normal Horse Serum 
ImmPRESS kit 
Anti-Rabbit Ig Kit 
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30 min. Primary antibody (37oC) (vWF) 1:1400 with antibody diluent 
200 µl/slide 
4x5 min. 1x-PBS Shake 
30 min. Secondary antibody ImmPRESS REAGENT Anti-
Rabbit Ig Peroxidase Kit 
4x5 min. 1x-PBS Shake 
1-40 sec. DAB Substrate kit 5 ml aqua dest 
+2 drops from buffer pH 7.5 
+4 drops from DAB Substrate 
+2 drops from  H2O2 
5 min. H2O  
1-3 min. Methylgreen on heating block (60oC) 
1 min. Aqua dest  
5 sec. Ethanol 96 %  
5 sec. Ethanol 96 %  
5 sec. 2-Propanol  
5 sec. 2-Propanol  
2 min. Xylol  
2 min. Xylol  
2 min. Xylol  
 Cover the slide with Pertex  
 
After staining, the sections were analyzed with the help of a computer-aided analysis 
system. The macros used were developed by the company Leica. All sections were - 
counted blinded. Morphometric quantification was done with a microscope using the 
Qwin software. Firstly, vessels were marked, then the vessel volume was detected. After 
that, the vessel lumen was confirmed, the vessel wall area was marked and in the end, 
the muscularization of vessel was determined. Staining of α-sma, depicting the 
muscularized parts of the vessel wall, is in purple, whereas staining of vWF, depicting 
the endothelium of the vessels and thus the non-muscularized areas of the vessel wall, 
is in brown. The degree of muscularization was assessed from small (external diameter 
of 20 – 70 μm), medium (external diameter of >70 – 150 μm) and large (external 
diameter of >150 μm) pulmonary vessels from WT and SPARC-/- mice which are kept 
28 days under normoxia (21% O2) or hypoxia (10% O2). Vessels were categorized as 
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fully- (>70% vessel circumference α-sma positive), partially- (5%-70% vessel 
circumference α-sma positive) or non-muscularized (<5% vessel circumference α-sma 
positive). The vessels were marked manually at a magnification of 400 times and their 
interior automatically detected by the computer to determine the degree of 
muscularization. 85 vessels of an outer diameter of 20-70 μm were analyzed from each 
lung lobe. The values measured automatically were transferred to Excel (Microsoft 
Corporation). 
For assessing the localization of SPARC lung tissue of normoxic (N, 21% O2, 28 days) 
or chronic hypoxic (H, 10% O2, 28 days) mice was used. The protocol for detection of 
SPARC is given in Table 6. As negative control, an isotype (IgG) control staining was 
performed. 
Table 6: Protocol for immunostaining against SPARC for mice 
DAY 1 
Incubation 
time 
Reagents Comments 
60 min. by 58oC  
10 min. Xylol 
 
10 min. Xylol 
 
10 min. Xylol 
 
5 min. Ethanol absolute 99.6% 
 
5 min. Ethanol absolute 99.6% 
 
5 min. Ethanol 96% 
 
5 min. Ethanol 70% 
 
2x5 min. Aqua dest. (Millipore) Shake 
15 min. 
20-25 min. 
 
10 min. 
30 min. 
Waiting for boiling 
Cooking with T-EDTA Buffer, pH 
9.0 
Switch off the cooker 
Cooling in room room temperature 
 
10x T-EDTA Buffer 
Per 1 cuvette: 90 ml Aqua 
dest.+10 ml T-EDTA Buffer 
 
60 min. 10 % BSA  
4x5 min. 1x-PBS Shake 
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30 min. Rodent Block M (blocking solution) 
at room temperature 
Zytomed System 
4x5 min. 1x-PBS Shake 
overnight Primary antibody (SPARC), +4oC 1:200 with antibody diluent 
200µl/slide  
DAY 2 
Incubation 
time 
Reagents Comments 
6x20 min. 1x-PBS Shake 
30 min. AP Polymer AP Polymer kit 
4x5 min. PBS Shake 
 
1 to 4 min. 
 
Warp Red Chromogen Kit 
Add 1 drop of Warp Red 
Chromogen to 2.5 ml of Warp 
Red Buffer  
5 min. 1x-PBS Shake 
1 min. Aqua dest Shake 
2-3 sec. Hematoxylin Dilute hematoxylin with 
Aqua dest (1:10) 
1 min. Aqua dest  
1 min. PBS  
5-10 min. Tap water  
1 min. Ethanol 96%  
1 min. Ethanol 96%  
2 min. 2-Propanol  
2 min. 2-Propanol  
2 min. Xylol  
2 min. Xylol  
2 min. Xylol  
 Cover the slide with Pertex  
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 Laser-microdissection  
Cryo-sections (10 μm) of Tissue Tek-embedded lung tissue from C57BL/6J mice were 
mounted on PEN membrane slides. For visualization of cell nuclei, sections were 
stained with hemalaun for 45 sec., following immersion in water, 70% ethanol, 96% 
ethanol, and then stored in 100% ethanol until use. Intrapulmonary arteries with a 
diameter of 50–100 μm were selected and microdissected under optical control using 
the Laser Microdissection 6000. Microdissected material was collected in Eppendorf 
tubes filled with RNA lysis buffer with 1% β-mercaptoethanol and finally snap-frozen 
in liquid nitrogen until use. 
 
 Microarrays 
Pulmonary vessels were laser-microdissected followed by RNA isolation and 
microarray analysis. Microarray was done by Dr. Friederike Weisel and Dr. Oleg Pak. 
In total vessels from 76 animals (23 controls – hypoxia, and 8-12 per time point) were 
analyzed by dual-color hybridizations in a balanced dye-swap design. RNA was isolated 
using the RNeasy Mini Kit following the kit’s instructions. RNA quality was measured 
by capillary electrophoresis using the Bioanalyzer 2100.  Purified total RNA was 
amplified and Cy-labeled using the dual-color QuickAmp Kit following the 
manufacturer’s instructions. 1μg of total RNA was used per reaction. Cy3- and Cy5-
labeled RNA were hybridized to 4x44K 60mer oligonucleotide spotted microarray 
slides (Mouse Whole Genome 4x44K, design ID 014868). Hybridization and 
subsequent washing and drying of the slides was performed following the Agilent 
hybridization protocol. The slides were scanned using a GenePix 4100A scanner. 
Images of Cy3 and Cy5 signals were analyzed using GenePix Pro 5.1 software, and 
calculated values for all spots were saved as GenePix results files. Stored data were 
evaluated using the R software120 and the limma package121 from BioConductor122. Log 
mean spot signals were taken for further analysis. Signals of replicate spots (same 
probes) within arrays were averaged. M/A data were LOESS normalized123 before 
averaging over arrays. Genes were ranked for differential expression using a moderated 
t-statistic124. Pathway analyses were done using gene set tests on the ranks of the t-
values121.
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 cDNA synthesis and quantitative real-time PCR 
Total RNA was isolated from human PASMC and from human and mouse lung 
homogenate by using the RNeasy Mini Kit according to the manufacturer’s instructions. 
200 ng / µl RNA was reverse-transcribed using the iScript cDNA Synthesis Kit 
according to manufacturer's instructions. The following reaction conditions were used 
for cDNA synthesis in the TPersonal thermocycler: 5 min. at 25°C, 20 min. at 46°C and 
1 min. at 95°C and stop at 4°C.  
Quantitative real-time polymerase chain reaction (q(RT)-PCR) was performed using the 
iQ SYBR Green Supermix according to the manufacturer’s instructions.  
 
iQ SYBR Green Supermix    5.0   μl 
Ampuwa®      3.5   μl 
Forward primer (10 pmol/μl)      
                        +     0.5   μl 
Reverse primer (10 pmol/μl)                                   
cDNA (template)     1.0   μl 
 
10   μl 
 
q-PCR was carried out in a CFX Connect™ Real-Time PCR Detection System under 
the following conditions: 1 cycle at 95°C for 10 min., then 40 cycles at 95°C for 10 sec., 
59°C for 10 sec., 72°C for 10 sec., followed by a dissociation curve. Primers were 
designed by using Primer BLAST from NCBI and purchased from Metabion 
(Martinsried, Germany) Table 7 shows the primer sequences for human and Table 8 
shows the primer sequences for mice. The Ct values were normalized to the endogenous 
control, porphobilinogen deaminase (PBGD) or beta-2-microglobulin (B2M), using the 
equation:  
ΔCt = Ctreference – Ctgene of interest 
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Table 7: Primer sequences for human 
Gene Forward primer ( 5`→3`) Reverse primer (5→  3`) 
PBGD CCCACGCGAATCACTCT
CAT 
TGTCTGGTAACGGCAATGCG 
SPARC CCCTGTACACTGGCAGTT
CG 
ACATTGGGGGAAACACGAAG 
Ki67 GCAAGCACTTTGGAGAG
C 
TCTTGACACACACATTGT 
PCNA CCTGTGCAAAAGACGGA
GTG 
TGAACTGGTTCATTCATCTCTAT
GG 
HIF-1α TTACAGCAGCCAGACGA
TCATG 
TGGTCAGCTGTGGTAATCCACT 
HIF-2α CTGATGGCCATGAACAG
CATCT 
TCCTCGAAGTTCTGATTCCCGA 
mTOR  TTAGAGGACAGCGGGGA
AGG 
AGGTCCGGTTCCAAGCATCT 
Tenascin 
C 
TCTGGTGCTGAACGAAC
TGC 
GTTTTCCAGAAGGGGCAGGG 
ILK1 GGCTGGACAACACGGAG
AAC 
ATCTCAACCACAGCAGAGCG 
 
Table 8: Primer sequences for mouse 
Gene Forward primer ( 5`→3`) Reverse primer (5→  3`) 
B2M AGCCCAAGACCGTCTAC
TGG 
TTCTTTCTGCGTGCATAAATTG 
PBGD GGTACAAGGCTTTCAGC
ATCGC 
ATGTCCGGTAACGGCGGC 
SPARC GGCCCGAGACTTTGAGA
AGA 
AATGTTCCATGGGGATGAGG 
FSTL1 CGAGCACGATGTGGAAA
CGA 
CTCTGTGACGGCACATTCCC 
SMOC1 CCGCATCCAACCTGCTGT
C 
CGGTCATGAACGGCGGAG 
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SMOC2 TGACAAGTCCATCACCG
TGC 
TCAGCATTTCCTCTGGGGGT 
SPOCK1 CGTGGTGCTTCCTCCAAG
TG 
GGTTCCAGTACTTGTCACGGTC 
 
PBGD: porphobilinogen deaminase, SPARC: secreted protein acidic and rich in cysteine,  PCNA: 
proliferating-cell-nuclear-antigen, HIF-1α: hypoxia inducible factor 1 alpha HIF-2α: hypoxia inducible 
factor 2 alpha  mTOR: the mammalian target of rapamycin,  ILK: integrin linked kinase, B2M: beta-2-
microglobulin FSTL1: follistatin like protein 1,  SMOC1: secreted modular calcium binding protein 1,  
SMOC2: secreted modular calcium binding protein 2,  SPOCK1:  SPARC/osteonectin, CWCV, and 
kazal-like domains proteoglycans 1.  
 
 Cell culture 
Primary human PASMC (hPASMC) were purchased from Lonza and maintained in 
Smooth Muscle Growth Medium 2, containing Smooth Muscle Supplement 2 mix. Cells 
were incubated at 37°C in a humidified atmosphere of 5% CO2. Experiments were 
performed in between passage 3 to 8 using 10.000 cells/1cm2.  
Mouse PASMC (mPASMC) were isolated from pre-capillary pulmonary artery vessels 
from WT and SPARC-/- mice.  
For cell isolation, mice were anesthetized and anticoagulated with a mixture of ketamine 
(100 mg/kg body weight), xylazine (20 mg/kg body weight) and heparin (1000 I.U/kg 
body weight). The lung preparation for cell isolation was performed with the help of the 
technical assistant Carmen Homberger and Dr. Monika Brosien. Tail and foot of the 
mice was pinched with forceps before starting to insure that the animal was fully 
anaesthetized. The skin was removed starting at the abdomen and the incision was 
vertically extended along the midline to the level of the mandible, exposing the trachea 
and a ligature was put around it. An incision was placed into the trachea which was 
subsequently cannulated with a tracheal tube or catheter. Following, the ligature was 
pulled tight. The abdomen was opened up and the diaphragm was removed from the 
thorax. Pericardium was removed carefully and the thorax was opened. Thymus was 
removed and an open ligature was placed around the aorta and the pulmonary artery. 
One incision was placed into the right ventricle and a catheter was inserted into the 
pulmonary artery. A second incision was placed in the left ventricle for drainage. Lungs 
were perfused with 3 ml Dulbecco's phosphate-buffered saline (DPBS). Afterwards, 15 
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mg agarose + 15 mg iron mixture was instilled. Following, 30 mg agarose was instilled 
into the trachea until the lung was completely filled. The catheter in the pulmonary 
artery was pulled out and the ligature was closed. Finally, the lung was transferred to 
ice cold (4°C) DPBS solution. The heart, trachea and coarse tissue residues were 
removed under the laminar flow hood and the five lung lobes were mechanically minced 
using the three-shaving technique. The iron-filled tissue pieces were washed several 
times in DPBS using a magnetic concentrator. Following, the tissue pieces were 
enzymatically digested in 37°C warm collagenase solution for 1 h. The tissue fragments 
were then mechanically sheared by 15 G and 18 G cannulas and separated from the iron-
filled vessel pieces with the magnetic concentrator. M199 medium with 10% FBS and 
1% Penicilin/Streptomycin was used to stop collagenase activity. The isolated vessel 
pieces were taken up in SMC medium with 10% FBS and 1% Penicilin/Streptomycin 
and seeded on cell culture dishes (seed 1, passage 0). Following 5 to 10 days, the vessel 
pieces were removed from the culture dish, washed in DPBS and transferred to a fresh 
culture dish in fresh SMC medium with 10% FBS and 1% Penicilin/Streptomycin (seed 
2, passage 0). Those steps were also done for seed 3, passage 0. After 18 days of 
isolation, seeds 1 to 3 were detached by 1-fold trypsin, centrifuged at 338 g (1200 rpm) 
for 5 min. After cell counting in a Neubauer counting chamber, 5000 cells/1cm2 cells 
were seeded on culture dishes for experiments (passage 1). 
Hypoxia experiments were performed in a chamber equilibrated with a water-saturated 
gas mixture of 1% O2, 5% CO2 and 94% N2 at 37°C. hPASMC and mPASMC were 
incubated in normoxic or hypoxia conditions for the indicated time points.  
For growth factor stimulation experiments hPASMC were serum-starved overnight and 
stimulated with human TGF-β1 (2ng/ml), PDGF-BB (5ng/ml), VEGF (2ng/ml), or EGF 
(50ng/ml), for the indicated time-points.  
The mTOR pathway was blocked using 0.5 μM rapamycin 20 h prior to TGF-β1 
stimulation for 4 h. For AKT inhibition, cells were treated with 50 nM wortmannin 20 
h prior to TGF-β1 stimulation for 4h. For ILK inhibition cells were treated with 1mM 
Cpd22 for 24 h.  A solvent control was carried out for each experiment. 
After experiment, cells were washed twice with ice cold PBS. Either, cells were 
harvested for protein or RNA isolation, using NP-40 respectively RLT buffer, or cells 
were used for proliferation assays. 
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 siRNA transfection 
Gene silencing was performed in hPASMC using siRNAs targeting SPARC, HIF-1α, 
HIF-2α, ILK and non-targeting control. hPASMC (90,000 cells/10cm2) were transfected 
in serum-free medium with 100 nM small-interfering RNA (siRNA) diluted in Opti-
MEM I medium,  using Lipofectamine®  2000 reagent (0.5 µl/cm2). The medium was 
replaced 8 h after transfection. Following siRNA transfection for the indicated time 
points, either RNA or proteins were isolated, or transfected cells were used for 
functional investigations. 
 
 Proliferation assay 
Primary hPASMC were seeded on 6-well plates and transfected with control siRNA 
(siR) or siSPARC. 24, 48 or 72 h post siRNA transfection, proliferation was assessed 
by cell counting in a Neubauer counting chamber. Values were normalized to siR as 
depicted in the paragraph statistical analysis 2.2.15. 
mPASMC from WT and SPARC-/- mice were seeded on 24-well plates. 1 μL BrdU-
labeling solution per 1 mL was added to the each well and incubated for 24 h. 
Proliferation was performed by using the Roche cell proliferation ELISA Kit, according 
to the manufacturer’s instructions. Measurment was performed in a Tecan SPARK® 
multimode microplate reader at an absorbance of 370 nm for 20 min. 
 
 Western blot analysis 
hPASMCs were scraped in 200 µl NP-40 buffer, containing 1 mM 
phenylmethylsulfonyl fluoride (PMSF). Human and mouse lung samples were grinded 
in 200 μl tissue lysis buffer containing 1mM PMSF using a homogenizer. After 
incubation on ice for 15 min., samples were centrifuged (10 min., 14000g, 4°C) and 
supernatant was transferred to a new tube. Protein concentrations were determined by a 
spectrophotometric assay (BCA assay). 20 μg/μl of protein extract was used for Western 
blotting. Samples were run on a 12% sodium dodecyl sulphate-polyacrylamide gel, 
following transfer to a polyvinylidene fluoride (PVDF) membrane. Membranes were 
blocked in blocking buffer. The following antibodies were applied over night at 4°C: 
SPARC, phospho-ERK1/2 (T202/Y204), ERK1/2, phospho-AKT (S473), AKT, ILK 
(all raised in rabbit and 1:1.000 diluted), rabbit cyclin D1 (1:10.000 diluted) and mouse 
β-actin (1:50.000 diluted). After washing 3 times for 10 minutes with PBS-T buffer, the 
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membrane was incubated for 1 h with horseradish-peroxidase–labeled secondary 
antibodies (1:5.000 diluted). Afterwards, the membranes were washed 3 x 15 min. with 
PBS-T buffer. Proteins were detected by Clarity™ Western ECL blotting substrate. 
Antigen-antibody complex was removed by incubating the membrane for 30 min. with 
stripping buffer prior to incubation with a new primary antibody. Table 9 and Table 10 
shows the protocols for preparation of buffers used for Western blotting and 
immunohistochemistry. 
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Buffer                                                     Substance                                Amount 
NP-40 buffer (Protein-Isolation)  TRIS Base   20 mM;  
pH 7.6 
NaCl    150 mM 
EDTA    1 mM,  
pH 8.0 
EGTA    1 mM,  
pH 8.0 
NP-40    0.5% (v/v) 
1x Elektrophoresis-Buffer   TRIS-Base   3.02 g 
(Western blotting)    Glycin    18.8 g 
SDS     (10%); 10 ml 
H2O    900 ml 
1x Blotting-Buffer    Methanol   200 ml 
(Western blotting)    TRIS-Base   2.42 g 
Glycin    11.2 g 
H2O    700 ml 
Stripping-Buffer    Glycin    1 M; 5 ml 
(Western blotting)    H2O    10 ml 
25 % HCl   0.750 ml 
  
Table 9: Preparation of buffers used for Western blotting 
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 Buffer                                                        Substance                              Amount  
1x PBS; pH 7.4    NaCl    8 g 
(Western blotting,    KCl    0.2 g 
Immunohistochemistry)   Na2HPO4   1.44 g 
KH2PO4   0.24 g 
H2O    1000 ml 
PBS-T      1x-PBS   999 ml 
(Western blotting)    Tween 20   1 ml 
Blocking Buffer    Skimmed Milk powder 6 g 
(Western blotting)    PBS-T    100 ml                                   
 
12% Gel for Western blotting  
TGX FastCast 12% gels were prepared in 1.5 mm Biorad glass plates for Western 
blotting as described in the Table 11.  
 
Table 11: TGX FastCast protocol 
Resolver solution for 1 gel Resolver solution in total 
Resolver A + Resolver B + 10% APS + TEMED 
      3 ml               3 ml              30 µl            3 µl 
6 ml 
Stacker solution for 1 gel Stacker solution in total 
Stacker A + Stacker B + 10% APS + TEMED 
      1 ml            1 ml              10 µl            2 µl   
2 ml 
Polymerization for 30 min.  
 
 
Table 10: Preparation of buffers used for Western blot and immunohistochemistry 
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 Promoter Analysis 
Sense and antisense strands of the human SPARC promoter were screened upstream of 
the coding sequence of the SPARC gene (NM_002859) for potential hypoxia response 
elements (HRE:gcgtg). The SPARC promoter sequence was obtained online 
(http://www.ncbi.nlm.nih.gov/mapview). 
 
 Statistical analysis 
The statistical evaluation of the cDNA microarrays was carried out by Dr. Jochen 
Wilhelm. Data were presented as mean ± SEM. Student’s t-test was performed for 
comparing two groups. Differences between more than two groups were analyzed by 
one or two way ANOVA followed by Dunnett’s, Bonferroni or Tukey`s multiple 
comparison post hoc tests. The evaluations were done by using GraphPad Prism 7 and 
Excel. The normalization was carried out according to the following formula: (xi, treatment-
xi, control) / (xi, control); where xi is the measured value of the experiment i.  A p value less 
than 0.05 was considered significant for all analyzes.  
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 Results 
Pulmonary hypertension (PH) is a severe and until now not curable disease22. In a 
previous study in mice, AMD-1 was identified as a novel key protein for the 
development and the reversal of PH. In this regard, it was shown that AMD-1 knockout 
mice possess less chronic hypoxia-induced PH than wild-type mice. Thus, targeting 
AMD-1 may represent a promising strategy for PH treatment.  
Along these lines, the present work/thesis aims to identify further key candidates for 
pulmonary vascular remodeling and its reversal by using a microarray approach, 
possibly identifying additional treatment strategies for PH.  
 
3.1 SPARC expression is attenuated in laser-microdissected pulmonary vessels 
following re-oxygenation of chronic hypoxic mice 
To screen for candidate genes involved in reverse remodeling, C57BL/6J mice were 
either exposed to normoxia (21% O2, 21 days, control group), hypoxia (10% O2, 21 
days, control group) or hypoxia (21 days) with a subsequent re-exposure to normoxia 
for 1, 3, 7, or 14 days (treatment group) (Figure 6A). Pulmonary vessels of those mice 
were laser-microdissected. To decipher gene expression alterations, whole-genome 
DNA microarray analysis was performed, revealing secreted protein acidic and rich in 
cysteine (SPARC), a matricellular glycoprotein, as one gene consistently down-
regulated in all re-oxygenation time-points investigated, compared to hypoxic controls 
(Figure 6B and C). SPARC is also known as osteonectin or basement membrane 
protein-40 (BM-40)125. SPARC is suggested to be involved in in cell-matrix interactions 
during tissue remodeling and embryonic development126. Moreover, elevated SPARC 
levels correlate with cell proliferation, cancer metastasis127 and the progression of 
bleomycin-induced pulmonary fibrosis128. 
As SPARC is suggested to be involved in hyper-proliferative diseases such as cancer 
and fibrosis, it is well conceivable that SPARC may play a major role in hypoxia-driven 
pulmonary vascular remodeling and its reversal. To confirm the down-regulation of 
SPARC following re-oxygenation, laser-microdissection of pulmonary vessels and 
q(RT)-PCR was performed from C57BL/6J mice, showing attenuated SPARC 
expression following 14 days of re-oxygenation (Figure 6D). Moreover, there was no 
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difference in SPARC expression between the normoxic and hypoxic control group in 
the microarray as well as in the q(RT)-PCR analysis (Figure 6B-D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
B 
C  D 
A. Schematic of the study design. Chronic hypoxic mice (H, 21 days, 10% O2) were re-exposed 
to normoxia (N, 21 days, 21% O2) for 1, 3, 7 and 14 days. B. Volcano plot: regulation versus 
statistical significance. Genes with log odds values ≥5 were considered to be regulated; black 
spot shows SPARC regulation in laser-microdissected pulmonary vessels isolated from mice 
after induction of PH (N-H) and reversal of PH (H-N1; H-N3, H-N7, H-N14). C. SPARC 
regulation in the pulmonary vasculature for the indicated time points of re-oxygenation. D. 
q(RT)-PCR depicting SPARC mRNA expression in the pulmonary vasculature during the 
reversal of PH. n=4 animals per time point. SPARC expression was normalized to B2M. 
*p<0.05 vs respective control (hypoxia). 
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Figure 6: Down-regulation of secreted protein acidic and rich in cysteine (SPARC) in the 
pulmonary vasculature during the reversal of hypoxia-induced pulmonary hypertension 
(PH). 
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C 
3.2 SPARC expression is elevated in the pulmonary vasculature of chronic 
hypoxic mice and idiopathic pulmonary arterial hypertension patients 
Next, possibly altered SPARC expression in chronic hypoxic mice and in human 
idiopathic pulmonary arterial hypertension (IPAH) patients was assessed. Analysis of 
lung tissue samples from normoxic (21% O2, 21 days) and chronic hypoxic (10% O2, 
21 days) mice showed no changes in SPARC mRNA expression. However, SPARC 
protein level was increased in chronic hypoxic mice (Figure 7A and B). 
Immunohistochemical staining showed predominant localization of SPARC in the 
pulmonary vessel wall (Figure 7C). Furthermore, hypoxia-induced SPARC expression 
seems to be specific for the pulmonary vasculature. In the systemic vasculature (Aorta) 
SPARC was not regulated (Figure 7D).  
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A. q(RT)-PCR depicting SPARC mRNA expression in lung homogenate from normoxic (N, 
21% O2, 28 days) or chronic hypoxic (H, 10% O2, 28 days) mice. n=6 animals per time point. 
SPARC expression was normalized to B2M. B. Representative Western blot analysis and 
densitometry of SPARC expression in lung homogenate from normoxic or chronic hypoxic 
mice. n=6. C. Immunohistochemical staining of SPARC (in red) in normoxic and chronic 
hypoxic mouse lungs. D. q(RT)-PCR showing SPARC mRNA expression in isolated Aorta 
from normoxic and chronic hypoxic mice. n=8.  
 
SPARC expression was elevated in an animal model of PH. Thus, next, its expression 
in human IPAH patients was assessed, demonstrating up-regulation of SPARC in lung 
homogenate from IPAH patients on both mRNA and protein level, compared to healthy 
donors (Figure 8A and B).  
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Figure 7: Elevated SPARC expression in the pulmonary vasculature of chronic hypoxic 
mice. 
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A. q(RT)-PCR depicting SPARC mRNA expression in lung homogenate from donor and 
idiopathic pulmonary arterial hypertension (IPAH) patients. n=11-14. SPARC expression was 
normalized to PBGD. B. Representative Western blot analysis and densitometry of SPARC 
expression in lung homogenate from donor and IPAH patients. n=12. 
 
3.3 Hypoxia regulates SPARC expression via HIF-2α  
Since abnormal proliferation of PASMC has a major role in pathogenesis of PH 72 and 
SPARC was localized in the medial layer, PASMC were used for in vitro studies. To 
unravel the molecular mechanisms regulating SPARC expression in vitro, primary 
hPASMC were exposed to normoxia (21% O2), hypoxia (1% O2) or hypoxia with a 
subsequent re-exposure to normoxia. SPARC mRNA expression was elevated 
following hypoxia and reversed following re-oxygenation (Figure 9A). SPARC protein 
level trended higher in hypoxic cells and was significantly down-regulated in re-
oxygenated PASMC (Figure 9B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. q(RT)-PCR analyzing SPARC expression in primary hPASMC exposed to normoxia (48h 
H, 21% O2), hypoxia (48h H, 1% O2) or hypxia with subsequent re-exposure to normoxia (24h 
H - 24h N). n=4. SPARC expression was normalized to PBGD. B. Representative Western blot 
analysis and densitometry of SPARC expression in normoxic, hypoxic or hypoxic with 
subsequent re-oxygenated PASMC. n=8. Control (24h N) was set to 100%. *p<0.05 vs 
respective control. 
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Figure 8: Elevated SPARC expression in the pulmonary vasculature of IPAH patients. 
Figure 9: Hypoxia-dependent SPARC expression in primary hPASMC is reversed by re-
oygenation. 
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Hypoxia triggers SPARC expression in vivo as well as in vitro, indicating that hypoxia-
inducible factor (HIF), which is one of the main transcription factors regulating hypoxic 
effects129, might be involved in regulating SPARC expression. For this purpose, HIF-
1α and HIF-2α, respectively were silenced in hPASMC by specific siRNA transfection. 
Both, HIF-1α and HIF-2α knockdown led to significantly reduced HIF-1α and HIF-2α 
mRNA levels, respectively (Figure 10A and C). Moreover, following HIF-1α silencing 
SPARC mRNA expression was not altered. However, HIF-2α knockdown significantly 
impaired SPARC mRNA expression in hypoxic PASMC (Figure 10B and D). Promoter 
analysis revealed two potential hypoxia response elements (HRE) in the SPARC 
promoter region (Figure 10E), confirming our results. 
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A. q(RT)-PCR analyzing HIF-1α mRNA expression in hypoxic (H; 24h; 1% O2) PASMC after 
siRNA transfection against HIF-1α (siHIF-1α) in comparison to control (siR). n=5. B. q(RT)-
PCR depicting SPARC mRNA expression in hypoxic PASMC after siRNA transfection against 
HIF-1α in comparison to control. n=5. C. q(RT)-PCR showing HIF-2α mRNA expression in 
hypoxic PASMC after siRNA transfection against HIF-2α (siHIF-2α) in comparison to control. 
n=9. D. q(RT)-PCR analyzing SPARC mRNA expression in hypoxic (24h) PASMC after 
siRNA transfection against HIF-2α in comparison to control. n=9. E. SPARC promoter analysis. 
Potential hypoxia response elements (HRE) in the 2000bp promoter region are shown. The 
coding sequence of the SPARC gene is marked with +1. 
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Figure 10: HIF-2α regulates SPARC expression in hypoxic primary hPASMC 
  Discussion 
57 
 
3.4 TGF-β1-induced SPARC expression 
To further identify factors regulating SPARC expression, primary hPASMC were 
stimulated with growth factors implicated in PH pathogenesis. Transforming growth 
factor-β1 (TGF-β1) induced a time-dependent increase in SPARC mRNA expression. 
A plateau was reached after 4 h of stimulation (Figure 11A). SPARC protein expression 
was elevated following 24 h of TGF-β1 stimulation (Figure 11B). Moreover, treatment 
of primary hPASMC with both, hypoxia and TGF-β1 induced no additive effect on 
SPARC mRNA expression (Figure 11C).  
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A. q(RT)-PCR analyzing SPARC mRNA expression in primary hPASMC stimulated with 2 
ng/ml TGF-β1 for 2, 4, 6 and 24h in comparison to control (unt., solvent control). n=4. SPARC 
expression was normalized to PBGD. B. Representative Western blot analysis and densitometry 
of SPARC expression in TGF-β1 stimulated PASMC. n=8. Control (untreated) was set to 100%. 
C. q(RT)-PCR demonstrating SPARC mRNA expression in TGF-β1 (4h) stimulated normoxic 
or hypoxic (24h) PASMC. n=7. SPARC expression was normalized to PBGD. *p<0.05 vs 
respective control (untreated).   
 
In addition, effect of PDGF-BB, EGF and VEGF stimulation was assessed on SPARC 
expression. However, none of those growth factors affected SPARC mRNA and protein 
expression (Figure 12A-F). 
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Figure 11: TGF- β1-induced SPARC expression in primary hPASMC 
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A. q(RT)-PCR analyzing SPARC mRNA expression in primary hPASMC stimulated with 5 
ng/ml PDGF-BB (n=3-7) for the indicated time points in comparison to control (unt., solvent 
control). SPARC expression was normalized to PBGD. B. Representative Western blot analysis 
and densitometry of SPARC expression in PDGF-BB stimulated PASMC. n=7. Control was set 
to 100%. C. q(RT)-PCR depicting SPARC mRNA expression in primary hPASMC stimulated 
with 50 ng/ml EGF (n=5-6) for the indicated time points in comparison to control (solvent 
control). SPARC expression was normalized to PBGD. D. Representative Western blot analysis 
and densitometry of SPARC expression in EGF stimulated PASMC. n=6. Control was set to 
100%. E. q(RT)-PCR showing SPARC mRNA expression in primary hPASMC stimulated with 
2 ng/ml VEGF (n=6) for the indicated time points in comparison to control (solvent control). 
SPARC expression was normalized to PBGD. F. Representative Western blot analysis and 
densitometry of SPARC expression in VEGF stimulated PASMC. n=7. Control was set to 
100%. 
 
3.5 SPARC regulates PASMC proliferation in vitro 
Since abnormal PASMC function significantly contributes to PH pathogenesis, next, 
the functional role of SPARC in vitro was assessed. In this regard, SPARC was silenced 
in primary hPASMC by specific siRNA transfection. 24, 48 and 72 h post transfection, 
SPARC was significantly downregulated on mRNA and protein level, compared to 
control (siR) (Figure 13A and B). Since SPARC knockdown was successful, role of 
SPARC in expression of pro-proliferative proteins was examined. Western blot and 
q(RT)-PCR depicted attenuated cyclin D1, PCNA and Ki67 levels following SPARC 
silencing (Figure 13C - E). Moreover, knockdown of SPARC significantly impaired 
PASMC proliferation, assessed by cell counting, 24 and 72 h post silencing (Figure 
13G).  
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Figure 12: SPARC expression expression is not regulated via PDGF-BB, EGF and VEGF 
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A. q(RT)-PCR analyzing SPARC mRNA expression in primary hPASMC after siRNA 
transfection against SPARC (siSPARC) for the indicated time points in comparison to control 
(siR). n=3-8. SPARC expression was normalized to PBGD. B. Representative Western blot 
analysis and densitometry after SPARC silencing. n=7. Control was set to 100%. C. 
Representative Western blot analysis and densitometry for cyclin D1 after SPARC silencing. 
n=4-7. Control was set to 100%. q(RT)-PCR depicting D. PCNA (n=3-8) and E. Ki67 (n=6-7) 
mRNA expression. F. Proliferation of  primary hPASMC assessed by cell counting after 
knockdown of SPARC (siSPARC) for 24, 48 and 72 hours in comparison to control. n=5-8. 
Control was set to 100%. *p<0.05 vs respective control (siR).   
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Figure 13: SPARC regulates PASMC proliferation 
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3.6 SPARC affects PASMC proliferation via the PI3K/AKT/mTOR signaling 
pathway 
Since SPARC affects PASMC proliferation, next, possible regulatory role of SPARC in 
pro-proliferative phosphatidylinositol 3-kinase (PI3K)-AKT and extracellular signal-
regulated kinase (ERK1/2) signaling pathways was assessed. Western blot analysis 
showed less phosphorylation of AKT following SPARC silencing (Figure 14A), while 
ERK1/2 phosphorylation was not affected (Figure 14B), suggesting that SPARC 
regulates PASMC proliferation via the PI3K-AKT signaling pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Representative Western blot analysis and densitometry for AKT phosphorylation after 
SPARC silencing for the indicated time points. n=7. Control (siR) was set to 100%.  B. 
Representative Western blot analysis and densitometry for ERK phosphorylation after SPARC 
silencing. n=6. Control was set to 100%. *p<0.05 vs respective control (siR). 
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Figure 14: SPARC regulates PASMC proliferation via the PI3K/AKT signaling 
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Since SPARC silencing negatively affected AKT phosphorylation, next, AKT was 
inhibited by wortmannin. TGF-β-induced SPARC mRNA expression was reversed 
following wortmannin application (Figure 15A). To further characterize the 
downstream signaling of SPARC/AKT, we focused on mammalian target of rapamycin 
(mTOR). mTOR is a downstream effector of AKT signaling130. It is implicated in 
pathogenesis of PH and possesses a role in PASMC proliferation131. SPARC silencing 
attenuated mTOR mRNA expression (Figure 15B). However, blocking the mTOR 
pathway by rapamycin did not affect SPARC mRNA expression (Figure 15C). 
Moreover, mTOR mRNA level was elevated in lung homogenate derived from IPAH 
patients compared to donor lungs (Figure 15D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
-6
-4
-2
Δ
C
t 
[P
B
G
D
-m
T
O
R
]
72h     24h     48h      72h
siR siSPARC
*
Δ
C
t 
[P
B
G
D
-S
P
A
R
C
]
TGF-β1        - +            +             -
8.0
10.0
8.5
9.5
11.0
9.0
Wortmanin - - +             +
10.5 *
*
A B 
C D 
Δ
C
t 
[P
B
G
D
-S
P
A
R
C
]
TGF-β1          - +          +         -
6
9
7
8
Rapamycin - - +         +
10
*
  Discussion 
64 
 
 
 
 
A. q(RT)-PCR assessing SPARC mRNA expression in TGF-β1-stimulated (4h) primary 
hPASMC after AKT pathway inhibition by 50 nM wortmannin for 20 h. n=4. B. q(RT)-PCR 
assessing mTOR mRNA expression after siRNA transfection against SPARC (siSPARC) for 
the indicated time points in comparison to control (siR). n=9.  C. q(RT)-PCR assessing SPARC 
mRNA expression after mTOR pathway inhibition with 0.5 μM rapamycin for 20h prior to 
TGF-β1 stimulation for 4 h. n=7.  D. q(RT)-PCR depicting mTOR mRNA expression in lung 
homogenate from donor and idiopathic pulmonary arterial hypertension (IPAH) patients. n=7-
8. mTOR expression was normalized to PBGD.*p<0.05 vs respective control (siR). 
 
3.7 ILK is located upstream in the SPARC signaling pathway 
Besides signaling pathways located downstream of SPARC, upstream signaling was of 
interest. It has been shown that integrin linked kinase (ILK) plays a role in PASMC 
proliferation in PAH132. Moreover, it was observed that SPARC binds to ILK in glioma 
migration, activating proliferation via the PI3K/AKT pathway133. To decipher the 
possible role of ILK in SPARC signaling in primary hPASMC, knockdown experiments 
were performed, revealing that SPARC silencing did not influence ILK mRNA and 
protein expression (Figure 16A and B). However, knockdown of ILK (Figure 16C and 
D) led to attenuated SPARC mRNA and protein expression (Figure 16E and F). In 
addition, ILK inhibition by Cpd 22 led to diminished SPARC mRNA expression 
(Figure 16G). Moreover, ILK was more prominent expressed in IPAH patients 
compared to healthy donors (Figure 16H). 
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Figure 15: Role of mTOR in SPARC signaling pathway 
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A. q(RT)-PCR depicting ILK mRNA expression in primary hPASMC after siRNA transfection 
against SPARC (siSPARC) for the indicated time points in comparison to control (siR). n=7. 
ILK expression was normalized to PBGD. B. Representative Western blot analysis and 
densitometry for ILK after SPARC silencing for the indicated time points. n=3. Control (siR) 
was set to 100%. C. q(RT)-PCR showing ILK mRNA expression after siRNA transfection 
against ILK (siILK) in comparison to control. n=5. D. Representative Western blot analysis and 
densitometry for ILK after ILK silencing for the indicated time points. n=3. Control (siR) was 
set to 100%. E. q(RT)-PCR analyzing SPARC mRNA expression in after siRNA transfection 
against ILK for the indicated time points in comparison to control. n=4. SPARC expression was 
normalized to PBGD. F. Representative Western blot analysis and densitometry for SPARC 
after ILK silencing for the indicated time points. n=3. Control (siR) was set to 100%. G. q(RT)-
PCR analyzing SPARC mRNA expression in PASMC after ILK inhibition by Cpd 22 (1 µm) 
for 24 h in comparison to control (DMSO). n=6. H. q(RT)-PCR analyzing ILK mRNA 
expression in lung homogenate from donor and idiopathic pulmonary arterial hypertension 
(IPAH) patients. n=7-8. ILK expression was normalized to PBGD. *p<0.05 vs respective 
control (siR). 
 
3.8 No in vivo effect of SPARC deletion in chronic hypoxia-induced pulmonary 
hypertension in mice 
In order to investigate the in vivo function of individual genes, knockout mice can be 
used. In this regard, homozygous SPARC knockout (SPARC-/-) mice and their littermate 
controls (wild-type, WT) were used to assess the role of SPARC in chronic hypoxia-
induced PH. The mice were either exposed to normoxia (21% O2, 28 days) or chronic 
hypoxia (10% O2, 28 days), followed by echocardiography and hemodynamic 
measurements to evaluate RV remodeling and function. An overview about the time 
schedule and the different groups is depicted in (Figure 17A). Protein levels from the 
lung homogenate of WT and SPARC-/- mice showed absence of SPARC in the knockout 
mice (Figure 17B). Chronic hypoxia did not cause any changes in right ventricular 
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Figure 16: ILK is upstream of SPARC 
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internal diameter (RVID), cardiac output (CO) and cardiac index (CI), whereas right 
ventricular wall thickness (RVWT) (Figure 17C-E) was enhanced in WT mice. 
However, right heart catheterization revealed an increase in right ventricular systolic 
pressure (RVSP) in both WT and SPARC-/- mice. (Figure 17F). Moreover, right heart 
hypertrophy, depicted by the fulton index (RV/(LV+S)) was more pronounced in 
chronic hypoxic WT and SPARC-/- mice (Figure 17G). Left ventricular weight was not 
affected by genotype and experimental condition. In all parameters assessed, SPARC-/- 
mice did not differ from WT mice in their response to chronic hypoxia (Figure 17C-
G).  
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A. Time table of the experimental design. Wild-type (WT) and SPARC-/- mice were kept under 
normoxic (N, 21% O2) or chronic hypoxic (H, 10% O2) conditions for 28 days. 
E=echocardiography, H=hemodynamic measurement. B. Representative Western blot analysis 
of SPARC protein expression in lung homogenate of wild-type (WT) and SPARC-/- mice. C. 
Right ventricular wall thickness (RVWT). n=13. D. Right ventricular internal diameter (RVID). 
n=8-13. E. Cardiac index (CI). n=13-14. F. Cardiac output (CO). n=13-15. G. Right ventricular 
systolic pressure (RVSP). n=12-14. H. Fulton index depicted by the mass of the right ventricle 
(RV) / (mass of the left ventricle (LV) + septum (S)). n=13-15. *p<0.05 vs respective control. 
ns=not significant different.  
 
 
PH is characterized by pulmonary vascular remodeling. In this regard, influence of 
SPARC on muscularization was assessed, revealing that hypoxia significantly reduced 
the number of small non-muscularized pulmonary vessels in the WT group. Same trend 
was observed in SPARC-/- mice, however did not reach statistical significance (Figure 
18A). Moreover, amount of full muscularized vessels trended to increase under hypoxia. 
Representative pictures for muscularization of small pulmonary vessels are shown in 
(Figure 18B). In summary, SPARC-/-does not affect muscularization of small 
pulmonary vessels. 
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Figure 17: SPARC knockout does not influence echocardiographic and hemodynamic 
parameters in chronic hypoxic mice 
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A. Degree of muscularization of small pulmonary vessels in chronic hypoxic (H, 10% O2, 28 
days) wild-type (WT) and SPARC-/- mice. Values are given for non-muscularized, partially 
muscularized, or fully muscularized vessels (outer diameter, 20–70 μm) from paraffin-
embedded lung sections co-stained against α-smooth mucle actin (α-sma) and von Willebrand 
factor. n=14-15. B. Representative images of the degree of muscularization from one animal per 
group. *p<0.05 vs respective control (WT N).  
 
3.9 Possible compensatory effect in SPARC-/- mice 
SPARC-/- mice did not differ from WT mice in their response to chronic hypoxia. 
However, a prominent effect of SPARC on PASMC proliferation in vitro might point 
towards a possible compensatory mechanism in vivo, in SPARC-/-mice. In this regard, 
expression level of SPARC family members in lung homogenate was assessed. 
Expression of follistatin-like protein 1 (FSTL1), secreted modular calcium binding 
protein 1 (SMOC1) and 2 (SMOC2) and SPARC (osteonectin), cwcv and kazal like 
domains proteoglycan 1 (SPOCK1) did not show any compensatory mechanism in 
hypoxic SPARC-/- lung homogenate (Figure 19A-D). 
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Figure 18: SPARC knockout does not affect pulmonary vascular remodeling 
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q(RT)-PCR analyzing A. FSTL1, B. SMOC1, C. SMOC2 and D. SPOCK1 mRNA expression 
in lung homogenate from chronic hypoxic (H, 10% O2, 28 days) wild-type (WT) and SPARC-/- 
mice. n=5-6. SPARC expression was normalized to B2M.  
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Figure 19: SPARC ablation does not influence expression of SPARC family members in 
lung homogenate derived from chronic hypoxic mice 
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Since SPARC family member expression was not counter regulated in lung homogenate 
from hypoxic SPARC-/- mice, possible direct compensatory mechanism on PASMC 
function was assessed.  In this regard, PASMC from SPARC-/- and their littermate 
controls were isolated and incubated for 24 h under hypoxic conditions. Interestingly, 
PASMC derived from SPARC-/- mice possessed a higher degree of proliferation than 
respective cells from WT animals (Figure 20A). Moreover, the level of AKT 
phosphorylation was enhanced in SPARC-/- mice (Figure 20B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Proliferation of WT and SPARC-/- mPASMC following 24 h hypoxic (1% O2) 
treatment,assessed by thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) incorporation. The 
assay was performed in passage 1. n = 4-6. B. Representative Western blot analysis and 
densitometry for AKT phosphorylation in mPASMC isolated from WT and SPARC-/- mice and 
incubated for 24 h under hypoxic conditions. n=4-6. 
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Figure 20: Elevated hypoxia-induced poliferation and AKT phosphorylation in PASMC 
isolated from SPARC-/- mice 
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 Discussion 
In general, the major findings of the present thesis are: 
1. Laser-microdissection followed by the microarray technique is a powerful tool to 
identify novel genes regulated in the pathogenesis of PH. In this regard, secreted 
protein acidic and rich in cysteine (SPARC) was identified as one gene down-
regulated in murine vessels following re-oxygenation of chronic hypoxic mice.  
2. Up-regulation of SPARC was observed in chronic hypoxic mice as well as in human 
idiopathic pulmonary arterial hypertension patients. 
3. Immunohistochemical staining predominantly localized SPARC to the pulmonary 
vasculature. 
4. Hypoxia-dependent SPARC regulation was confirmed in primary hPASMC.  
5. Molecular analysis revealed HIF-2α-dependent SPARC expression under hypoxia.  
6. Next to hypoxia, TGF-β1 up-regulated SPARC expression. However, PDGF-BB, 
EGF, and VEGF stimulation did not affect SPARC expression. 
7. Functional importance of SPARC in PASMC proliferation was shown in vitro, 
following SPARC silencing. 
8. Regulation of PASMC proliferation occurred via the PI3K/AKT/mTOR pathway.  
9. Integrin linked kinase was identified upstream of the SPARC signaling pathway. 
10. However, in an in vivo approach SPARC-/- mice were not protected from hypoxia-
induced PH. 
11. As a compensatory mechanism, an increased AKT phosphorylation and PASMC 
proliferation was observed in SPARC-/- mice under hypoxic conditions. 
We suggest SPARC as a novel protein associated with PH and PASMC function. 
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4.1 Selection of the animal model 
In the present thesis, the mouse model of chronic hypoxia-induced PH was used, 
representing group three (PH secondary to lung disease and/or hypoxia) in the 6th World 
Symposium classification30, 33, 134. In mice, chronic hypoxic exposure  (10% O2) leads 
to muscularization of small, normally nonmuscular arteries, elevated pulmonary arterial 
pressure and structural remodeling of the pulmonary vessels, resulting in an increase in 
pulmonary vascular resistance and right heart hypertrophy30. Moreover, the chronic 
hypoxic mouse model is highly predictable and highly reproducible within a selected 
strain. However, the three critical points of human PH, obliteration of pulmonary 
arterioles, non-reversibility and development of the right ventricle failure108 are not 
represented in this model. In this regard, there is only a slight increase in pulmonary 
arterial pressure following chronic hypoxia135. Thus, the model of chronic hypoxia-
induced PH in mice is a widely used model to investigate milder forms of human PH 
such as PH associated with residence at high altitude85. Further one, chronic hypoxia-
induced PH in mice is reversible when the stimulus stops113, 118 even without therapeutic 
intervention. As the aim of the present thesis was to screen for novel candidate genes 
involved in pulmonary vascular remodeling and its reversal following re-oxygenation, 
the chronic hypoxic mouse model was the ideal/best available model. Availability of 
SPARC knockout mice additionally indicated for this model.  
However, as the chronic hypoxic PH model in mice is a model for less severe forms of 
PH, in further experiments, it might be recommendable to confirm elevated SPARC 
levels in PH in other more severe models. In this regard, the MCT-induced PH model 
is a well characterized and often used model. MCT is a toxic pyrrolizidine alkaloid agent 
present in the plant Crotalaria spectabilis110. It is mostly used in rats, while mice are 
not able to metabolize MCT to its active metabolite dehydromonocrotaline. 
Metabolization requires a CYP3A isoenzyme, which is lacking in the mouse liver108. A 
single MCT injection in rats induces endothelial damage, vascular inflammation and 
edema formation, followed by an increase in pulmonary vascular resistance. Finally 
vascular remodeling, including media hypertrophy, right heart hypertrophy and even 
right heart failure occurs82, 108, 109. However, the response to MCT is variable among 
species, strains and even animals. The different pathophysiology in this model makes it 
an attractive and interesting second model for studying SPARC dysregulation in PH.  
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4.2 Identification of a candidate gene for reverse remodeling 
In a previous study, Weisel et al., screened for potential candidates genes contributing 
to reverse remodeling by using the DNA microarray technique113. In this regard, mice 
were exposed to normoxia, chronic hypoxia or chronic hypoxia with subsequent re-
exposure to normoxia for different time points, followed by microarray analysis from 
lung homogenate. S-adenosylmethionine decarboxylase 1 (AMD-1) was identified as a 
novel candidate gene for pulmonary vascular remodeling processes. AMD-1 was 
elevated expressed in chronic hypoxic mice and down-regulated following re-
oxygenation of mice. Furthermore, AMD-1 was critically involved in dysregulated 
PASMC proliferation and apoptosis. In addition, AMD-1 knockout mice possessed less 
chronic hypoxia-induced PH than respective controls113. 
Going beyond this approach, the present thesis focused on the gene expression 
alterations in the lung vasculature by using the laser-microdisection/microarray-
technique. Laser microdissection of pulmonary vessels will possibly enhance the chance 
to detect additional relevant new genes/pathways for vascular remodeling which 
predominantly takes place in small pulmonary arteries72. Using the laser 
microdissection technique allows the isolation and thus the expression analysis of a 
specific compartment136, 137. In contrast, using lung homogenate for microarray analysis 
will display expression alterations of a complete organ137. In this regard, possible gene 
expression changes occurring specifically in the vascular compartment might be not 
detectable137.    
The microarray technique is used for large scale screening and expression studies138. In 
this regard, it allows the simultaneous characterization of gene expression alterations of 
thousands of genes and thus signaling pathways in healthy and disease state113, 139. 
Moreover, the microarray technique can be used for identification of prognostic markers 
for certain diseases139. Thus, while microarrays are useful in a large variety of 
applications, they have some disadvantages140. Firstly, microarrays can lead false 
positive results with the generation of enormous data masses  and with degraded 
mRNA138, 140. Secondly, the use of cDNA microarrays is also very expensive and results 
are dependent on the purity of RNA138, 140. And thirdly, a DNA array can only detect 
sequences which are specific for the detection138, 140. 
In this regard, mice were exposed to normoxia (21 days), chronic hypoxia (21 days) and 
chronic hypoxia (21 days) with subsequent re-exposure to normoxia followed by laser-
microdissection of pulmonary vessels. 
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Of all differentially expressed genes, the present thesis focused on SPARC. SPARC, 
also called osteonectin or basement membrane protein-40 (BM-40), is a 42 kDa 
multifunction glycoprotein125. SPARC is expressed in endothelial cells, vascular smooth 
muscle cells, macrophages, fibroblasts, and the alveolar epithelium141-143. SPARC is 
involved in regulation of various cellular processes such as cell proliferation, migration 
and angiogenesis144 as well as changing cell shape, inhibiting cell-cycle progression, 
and influencing the synthesis of extracellular matrix (ECM) proteins145. Among other 
functions, SPARC regulates wound healing, responses to injury and tissue 
remodeling141. In this regard, association of SPARC with several cancer forms and 
pulmonary fibrosis was observed57, 146. 
SPARC was consistently down-regulated in all re-oxygenation time-points investigated. 
Moreover, it is critically involved in several cellular processes that are dysregulated in 
PH and is associated with several hyper-proliferative diseases. Thus, it might be a 
promising novel potential target gene for pulmonary vascular remodeling processes 
underlying PH. In addition, involvement of several SPARC interaction, partners with 
what PH pathogenesis are already known for: Signal transducers and activators of 
transcription-3 (STAT3)147, transforming growth factor beta-1 (TGF-β1)80, AKT1148, 
MAPK1149, Caveolin 1 (CAV1)150, murine double minute 2 (Mdm2)151] and integrin 
linked kinase (ILK)132. 
Since the microarray technique can lead to false results, results should be validated by 
additional methods. In this regard, SPARC regulation in pulmonary vessels isolated 
from normoxic, hypoxic and re-oxygenated hypoxic mice was confirmed on mRNA 
level by q(RT)-PCR. In detail, in both techniques, there were no differences in SPARC 
regulation between the normoxic and hypoxic group and down-regulation following re-
oxygenation.  
In further experiments, SPARC regulation in lung homogenate obtained from mice 
suffering from chronic hypoxia-induced PH as well as from human IPAH patients was 
analyzed on mRNA and protein level. In addition, functional importance of SPARC was 
assessed by in vitro experiments. Finally, SPARC knockout mice were used to decipher 
the role of SPARC in PH in vivo. 
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4.3 Characterization of SPARC expression in chronic hypoxia-induced PH and 
in IPAH patients 
In the present thesis, lung homogenate from mice exposed to chronic hypoxia and 
patients with IPAH was used. Similar to the pulmonary vasculature, there was no 
induction of SPARC mRNA expression in lung homogenate derived from chronic 
hypoxic mice. However, SPARC protein expression was enhanced in lungs of chronic 
hypoxic mice, depicting that RNA and protein regulation not necessarily correlates. In 
addition, in IPAH patients, both SPARC mRNA and protein levels were enhanced in 
comparison to donor lungs. Elevated SPARC levels in chronic hypoxic mice as well as 
IPAH patients might point that there are no species-dependent differences in SPARC 
regulation.  
Involvement of SPARC in hyperproliferatives disease is already known from previous 
studies. In this regard, it has been showed that, SPARC may contribute to the 
progression of pulmonary fibrosis128, 152-154, breast cancer, melanoma and 
glioblastoma146. Enhanced SPARC levels were also observed in heat shock-, heavy 
metal- or endotoxin-induced tissue injury models in mice, chick embryo and dog155-158.  
Together, the role of SPARC in fibrosis, cancer and injury models points towards an 
important function of SPARC in hyper-proliferative diseases such as PH, most likely 
by affecting tissue remodeling processes. In this regard, in the present thesis, SPARC 
was predominantly localized to the pulmonary vessel wall, the site of the pulmonary 
vascular remodeling57. Vascular specific SPARC expression in the lung was already 
observed in bleomycin‐induced pulmonary fibrosis in mice152. In addition, elevated 
SPARC expression in chronic hypoxic mice was specific for the pulmonary vasculature 
as there were no changes in expression in the systemic vasculature (aorta). 
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4.4 Hypoxia as a critical factor of SPARC expression  
Elevated SPARC expression in chronic hypoxia-induced PH in mice might point 
towards hypoxia as a critical factor in SPARC regulation. As SPARC was localized in 
the medial layer of the vasculature wall and PASMC are critically involved in 
pulmonary vascular remodeling72, primary human PASMC were chosen for in vitro 
experiments. In this regard, PASMC were exposed to normoxia, hypoxia or hypoxia 
with a subsequent re-exposure to normoxia, mimicking the reverse remodeling approach 
in vivo. Hypoxia led to an increase in SPARC expression which was reversed by re-
oxygenation of cells. Hypoxia-dependent SPARC expression was already shown in 
human malignant glioma cells159. 
Since chronic hypoxic mice and hypoxic primary human PASMC possessed enhanced 
SPARC levels, next potential involvement of hypoxia inducible factors (HIF) in 
regulation of SPARC expression was assessed. Under normoxic conditions HIF‐α is 
hydroxylated by prolyl hydroxylase domain (PHD) proteins at conserved prolines 402 
and 564160, 161 in the oxygen‐dependent degradation domain162. However, under hypoxic 
conditions, HIF‐α hydroxylation by PHD is inhibited,160 causing HIF‐α accumulation 
and translocation to the cell nucleus. In the nucleus,  HIF‐α  dimerizes with the HIF‐β 
subunit, forming together with transcriptional co‐activators such as CREB‐binding 
protein and p300, an active transcription factor129. Binding of the active transcription 
factor to hypoxia response elements leads to expression of hypoxia‐specific genes129 
which can ensure sufficient O2 delivery, O2 transport and metabolic adaptations as well 
as vascular remodeling129, 163. 
In this regard, HIF levels were enhanced in the pulmonary vasculature of chronic 
hypoxic mice, in plexiform lesions of IPAH patients as well as in fawn-hooded rats86, 
164, 165. 
In the present thesis, HIF-1α silencing did not alter SPARC expression in hypoxic 
primary hPASMC. However, HIF-2α knockdown impaired SPARC expression in 
hypoxic cells. HIF-dependent SPARC expression was already shown in human 
malignant glioma cell lines following HIF-1α silencing159. Role of HIF-2α in regulation 
of SPARC transcription is until now unknown. However, analysis of the SPARC 
promoter revealed two potential HIF binding sites in the 2000bp promoter region. If 
HIF-2α directly or indirectly regulates SPARC expression in primary hPASMC has to 
be addressed in further experiments, such as electrophoretic mobility shift assays 
(EMSA) or chromatin immunoprecipitation (ChIP).  
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In addition to HIF, binding of SRY (sex‐determining region Y) ‐ box 5 (SOX‐5) to the 
SPARC promoter is known166. However, next to HIF and SOX-5, there might be 
additional not yet identified transcription factors, playing a role in SPARC regulation 
as well. 
Taken together, SPARC expression was increased in IPAH patients and chronic hypoxic 
mice. In vitro, SPARC expression was regulated via the hypoxia/HIF-2α pathway in 
primary hPASMC. Next to hypoxia, SPARC expression was regulated by TGF-β. 
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4.5 Effects of growth factor stimulations on SPARC expression 
Several growth factors, including TGF-β180, PDGF81, 82, EGF83and VEGF84, have been 
implicated in the pathogenesis of PH, by influencing abnormal proliferation and 
migration of pulmonary arterial vascular cells87.  
Thus, next, influence of those growth factors  on SPARC expression was assessed. In 
literature, SPARC interaction with several growth factors, including TGF-β1, VEGF 
and PDGF is described146. In bleomycin-induced lung fibrosis in mice TGF-β increases 
SPARC expression in mice fibroblasts128. Additionally, TGF-β upregulates SPARC 
expression in human gingival fibroblasts, human dermal fibroblasts, and human pulp 
cells167, 168. Blocking the TGF-β signaling leads to significantly attenuated SPARC 
levels and degree of fibrosis128. EGF and PDGF downregulates SPARC expression in 
human pulp cells and also in rabbit chondrocytes168. Moreover, SPARC binding to 
VEGF inhibits VEGF-stimulated proliferation of endothelial cells169. 
Experiments in the present thesis in primary hPASMC revealed an induction of SPARC 
expression following TGF-β1 stimulation, which is in line with the literature in 
fibroblasts. However, PDGF-BB, EGF and VEGF were not able to induce SPARC 
expression.  
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4.6 Functional role of SPARC 
Since SPARC expression is up-regulated in PH, next, its possible functional role was of 
major interest. In this regard, its impact on primary hPASMC proliferation was assessed. 
Abnormal PASMC proliferation is one of the key features in PH pathogenesis72. SPARC 
mRNA and protein expression was down-regulated by specific siRNA transfection in a 
time-dependent manner. Indeed, SPARC knockdown negatively affected PASMC 
proliferation. Impact of SPARC in proliferation was already observed in ovarian cancer 
cells, gastric cancer cells, glioma cells and melanoma cells127. Modulation of hPASMC 
proliferation most probably occurred via the proliferation markers cyclin D1, Ki67 and 
PCNA, since those were attenuated following SPARC silencing.  
Ki-67 is a nuclear antigen expressed during the G1, S, and G1–M phases of the cell 
cycle in proliferating cells170. PCNA is a highly conserved nuclear protein, which is 
expressed during cell replication and DNA repair170. Next to Ki67 and PCNA, cyclin 
D1 is one of the key genes controlling cell cycle and thus proliferation by influencing 
transition of cells between the G1 phase and the S phase171. 
Together, these results clearly indicated that SPARC affects PASMC proliferation. 
Finally, the involved pathway was of major interest. 
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4.7 SPARC signaling pathway  
PI3K/AKT and extracellular signal–regulated kinase (ERK1/2) signaling pathways are 
closely connected with pro-proliferative processes in hyperplastic diseases such as 
fibrosis, cancer and PH148, 172, 173. In detail, the PI3K/AKT signaling pathway is known 
to be involved in vascular development and normal vascular function by influencing 
proliferation of rat PASMC148. In this regard, PI3K/AKT signaling inhibition by 
triciribine led to impared rat PASMC proliferation148. The MAPK pathways consist of 
ERK1/2, c-Jun NH2-terminal kinase (JNK) and p38 MAPK, regulating cellular  
proliferation149. In this regard, elevated levels of ERK1/2 expression and 
phosphorylation were observed in proliferating pulmonary vascular  SMC from 
broilers174. 
Consequently, SPARC expression was silenced and the impact on AKT/ERK activation 
(phosphorylation) was assessed, indicating attenuated phosphorylation of AKT 
following SPARC silencing. Moreover, inhibition of AKT by wortmannin led to 
attenuated TGF-β1-induced SPARC expression, indicating a bidirectional regulatory 
role of SPARC and AKT. However, SPARC silencing did not impair ERK activation. 
A connection of SPARC with the AKT signaling pathway was already found in a recent 
publication, revealing less phosphorylation of AKT following SPARC depletion in 
human melanoma cell lines175. 
 
In addition to PI3K/AKT, mTOR, an AKT downstream effector, plays a major role in 
proliferation176 and PH pathogenesis 177. In detail, increased levels of mTOR (Ser-2481) 
phosphorylation and activation were found in hypoxic primary human and rat 
pulmonary arterial vascular smooth muscle cells (PAVSMC), causing elevated cell 
proliferation177. In this regard, in the present thesis, mTOR dysregulation in IPAH 
patients was confirmed. 
Moreover, SPARC silencing reduced mTOR expression in hPASMC. However, mTOR 
inhibition by rapamycin did not influence TGF-β-induced SPARC expression, 
indicating that mTOR is located down-stream of SPARC in the signaling pathway. 
Taken together, SPARC affects PASMC proliferation most probably via the 
PI3K/AKT/mTOR signaling pathway Figure 21.  
After identifying members of the downstream signaling pathway of SPARC, upstream 
signaling was addressed. ILK is a serine-threonine kinase localized in focal adhesion 
complexes178. Elevated ILK expression and activation occurs in several types of 
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cancers, including leukemia and glioblastoma179. ILK acts as an intracellular adaptor 
and kinase, linking integrins, (cell-adhesion receptors), and growth factors to a range of 
signaling pathways179. The kinase activity of ILK is modulated by cell–ECM 
interactions179. Intracellular, there is a direct interaction between ILK and actin and α-
actinin-binding proteins such as the parvins, affixin and paxillin180-182. Moreover, 
blockage of ILK expression and activity is anti-tumorigenic. Thus, ILK is an attractive 
target for cancer therapeutics179. Previous reports depicted SPARC binding to ILK, 
leading to human glioblastoma multiform cell migration by inducing the downstream 
phosphorylation of the AKT and ERK pathways133.  
In the present thesis, first ILK expression was assessed after SPARC silencing, revealing 
no influence on expression. However, ILK silencing negatively affected SPARC 
expression, clearly indicating that ILK is located upstream in the SPARC signaling 
pathway. Cpd 22 is a cell-permeable compound which acts as an ILK inhibitor183. Cpd 
22 possess a pro-apoptotic role in human prostate and breast cancer cell lines183. Similar 
than ILK silencing, ILK inhibition by Cpd 22 migtates SPARC expression. Next to 
SPARC and mTOR, ILK is enhanced expressed in IPAH patients. Elevated ILK 
expression in IPAH patients was already observed in a previous study132. However, the 
connection of ILK to SPARC and AKT/mTOR signaling in hPASMC is to the best of 
our knowledge new. In this regard, pharmacological intervention of SPARC might be a 
possible novel treatment strategy for PH pathogenesis.  
In head and neck cancer, SPARC expression is a poor prognostic factor for disease 
outcome184. However, SPARC might favor tumor response to nab-paclitaxel treatment 
in a clinical setting in those tumors. In detail, SPARC has been suggested as an 
important factor that affects drug accumulation. Via its albumin binding site and its high 
abundance in several tumor forms such as neck and head tumor, SPARC gathers the 
albumin-bound drug, nab-paclitaxel to tumor tissue184-186. However, further verification 
and several larger ongoing clinical studies are required in multiple tumor types for 
approving SPARC as a predictive biomarker for nab-paclitaxel treatment184. 
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4.8 In vivo relevance of SPARC  
Since SPARC affects PASMC function in vitro, SPARC might possess an in vivo 
function as well. In this regard, global SPARC-/- mice and their littermate controls (wild-
type, WT) were exposed to chronic hypoxia for 28 days. Following, echocardiography, 
hemodynamic measurements and muscularization were assessed. The RV has an 
important role in the determination of functional state and prognosis in PH134. Under 
physiological conditions the RV has a very thin walled crescent shaped structure and is 
designed to pump blood through a low pressure and high flow pulmonary vascular 
system187. However, under pathophysiological conditions such as chronic hypoxia, 
pulmonary vascular resistance and pressure increases due to narrowing of the 
pulmonary vascular lumen, leading to pressure overload of the right ventricle. An 
adaption mechanism leads to right heart hypertrophy188. However, at a certain time 
point, hypertrophy is no longer compensated and right ventricular failure might occur189.  
In the present thesis, RV remodeling and function is depicted by RVWT, RVID, CO 
and CI. RVID, CO and CI were regulated neither by hypoxia nor by genotype. RVWT 
was increased in WT mice following chronic hypoxia, but did not reach statistical 
significance in SPARC-/- mice. In conclusion, echocardiography parameters assessed 
indicate same degree of RV function and remodeling in the WT and knockout group. 
Elevated RVSP and fulton index in chronic hypoxic WT mice and decreased amount of 
non-muscularized vessels were already observed in numerous previous studies108, 113, 
190. Taken together, echocardiography and hemodynamic data indicate that possible 
hemodynamic changes occurred prior to changes in the heart. 
Moreover, remarkably there was;  
1) An obvious variability in the single experimental groups in echocardiographic and 
hemodynamic values assessed. 
2) An upward shift in already under baseline conditions (normoxia), especially for 
RVSP. 
SPARC-/- mice used for the in vivo experiments in the present thesis possessed a mixed 
genetic background, consisting of C57BL/6 and 129Sv191, 192. Since littermate controls 
were used, the control was as similar to the experimental group as feasibly and other 
possible confounders could be excluded.  
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Normally, RVSP in normoxic C57BL6/J mice ranges between 10-20 mmHg, whereas 
in hypoxic C57BL6/J mice it is between 14-26 mmHg108. Moreover, RVSP in normoxic 
129Sv mice ranges between 27-30 mmHg, whereas in hypoxic 129Sv mice it is 42-45 
mmHg193. Results in the present thesis showed RVSP 20-30 mmHg in normoxic and 
30-40 mmHg in hypoxic WT mice.  
Moreover, due to animal availability, the experimental groups contained higher 
numbers of females than males, which in addition can cause variations in experimental 
groups. In detail, previous studies observed that female gender and/or estrogens can be 
protective in experimental models of PH, such as the hypoxic and monocrotaline 
models194. 
Taken together all those factors might cause that SPARC-/- mice did not differ to WT 
mice in their response to chronic hypoxia, neither in RV remodeling and function, nor 
in hemodynamic data, fulton index and degree of muscularization of small pulmonary 
vessels. However, additional reasons might be the occurance of compensatory 
mechanisms in global SPARC-/- mice or the usage of the wrong model. Possibly, 
SPARC-/- does not affect pulmonary vascular remodeling but reverse remodeling.    
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4.9 SPARC family members  
SPARC is a member of a gene family possessing structural similarities in one or more 
protein domains195. The family members are: secreted modular calcium binding protein 
(SMOC) 1 and 2, follistatin like protein 1 (FSTL-1), testican 1 (SPARC/osteonectin, 
CWCV, and Kazal-like domains proteoglycans, SPOCK)196. SMOC1 binds tenascin 
C197 which is involved in PH pathogenesis72. SMOC2 is highly expressed in heart and 
muscle198 and has a role in proliferation in human hepatocellular carcinoma cells199. 
FSTL-1 has a role in respiratory distress and multiple defects in lung development200. 
SPOCK1 is involved in the development and progression of tumors201. 
Since SPARC-/- mice are not protected from chronic hypoxia-induced PH and SPARC 
family members are involved in hyperproliferative diseases and/or lung pathologies, 
next screening of possible compensatory mechanisms in SPARC-/- mice were 
performed. In this regard, expression levels of SPARC family members was assessed in 
WT and SPARC-/- mouse lung homogenate. However, degree of expression for FSTL-
1, SMOC1, SMOC2 and SPOCK1 did not differ between WT and SPARC-/-, revealing 
no compensatory expression in SPARC family members in SPARC-/- mice.  
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4.10 Possible compensatory mechanisms 
In the present thesis SPARC regulates PASMC proliferation via the PI3K/AKT/mTOR 
pathway. However SPARC-/- mice did not differ from WT mice in their response to 
chronic hypoxia, neither in RV remodeling and function, nor in hemodynamic data, 
fulton index and degree of muscularization of small pulmonary vessels. Moreover, as a 
compensatory mechanism, degree of expression for SPARC family members also did 
not differ between WT and SPARC-/-. Taken together, other possible compensatory 
mechanisms might be the reason for the in vivo results in the present thesis.  
Indeed, a direct compensatory mechanism on PASMC function was observed in vitro. 
PASMC isolated from SPARC-/- mice and incubated under hypoxic conditions 
possessed a higher level of AKT phosphorylation and proliferation than respective cells 
from WT animals. Compensatory upregulation of those two processes might explain 
why WT and SPARC-/- mice did not differ in their response to chronic hypoxia Figure 
21. 
For the in vivo studies, global SPARC-/- mice and littermate controls were used. A global 
KO leads to a permanent deletion of a specific gene in the whole animal, in every cell 
of the organism202. In future, conditional KO mice might be more beneficial while in 
this model the gene of interest is temporally controllable at a given time-point in 
preferable adult animals prior to start of the experiment with the usage of external 
inducer-agents such as tamoxifen or tetracycline203. Finally, inducible cell type specific 
SPARC-/- mice might help to decipher the role of SPARC in vivo in a specific cell type.  
Next to the conventional KO, SPARC-/- mice can be induced via clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated genes 
(CRISPR/Cas) and adeno associated virus (AAV)202, 203. 
CRISPR/Cas is a new system which allows editing of the mice genome much faster than 
previously used techniques. Moreover, in this system multiple mutations can be made 
in a single experiment. Until now, it is the easiest method for obtaining a viable 
knockdown mouse model, which can be used for experiments204, 205. 
Selective gene silencing by RNA interference (RNAi) is another possible approach. 
Short hairpin RNA (shRNA) is an artificial RNA molecule which targets a specific gene, 
causing stable gene silencing206, 207. Additionally, viral vectors have been used as the 
delivery method in many studies207. It has been observed that, shRNA delivery by AAV 
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systems are more efficient in gene silencing than alternative methods such as retroviral 
or lentiviral systems207. 
In conclusion, experiments using time-point specific (conditional) and/or cell type 
specific SPARC-/- mice will be needed to avoid the occurrence of compensatory 
mechanisms and to assess the role of SPARC in vivo. Finally, a therapeutic intervention 
can be taken in consideration for treatment of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPARC is elevated expressed in IPAH patients, in chronic hypoxic mice and in primary 
hPASMC following TGF-β1 stimulation or hypoxic treatment. Hypoxia-induced SPARC 
expression is regulated via HIF-2α. Re-oxygenation of PASMC reversed enhanced SPARC 
expression under hypoxic conditions. Silencing of SPARC inhibits PASMC proliferation via 
the PI3K/AKT/mTOR signaling pathway. ILK is located upstream in the SPARC signaling 
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pathway. SPARC-/- are not protected from chronic hypoxia-induced PH, possibly because of 
enhanced AKT phosphorylation and PASMC proliferation in hypoxic SPARC-/- PASMC. 
AKT: Protein kinase B, ECM: extracellular matrix, GF: growth factor, HIF: hypoxia inducible factor, 
ILK: integrin linked kinase, IPAH: idiopathic pulmonary arterial hypertension, mTOR: the mammalian 
target of rapamycin, PASMC: pulmonary arterial smooth muscle cells, PCNA: proliferating-cell-nuclear-
antigen, SPARC: secreted protein acidic and rich in cysteine, TGF-β1: transforming growth factor beta.  
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 Summary 
Pulmonary hypertension (PH) is a life-threatening disease, characterized by excessive 
pulmonary vascular remodeling, leading to elevated pulmonary arterial pressure and 
right heart hypertrophy. PH is caused among others by chronic hypoxia, 
vasoconstrictor/vasodilator and/or growth factor imbalance leading to pulmonary 
arterial smooth muscle cell (PASMC) dysregulation. Upon re-exposure to normoxia, 
hypoxia-induced PH in mice is reversible.  
Until now, research in the field of PH concentrates mostly on the onset and development 
of PH. In this thesis, we aim to identify novel candidate genes for pulmonary vascular 
remodeling and its reversal specifically in the pulmonary vasculature.  
Reverse remodeling was investigated in adult mice (C57BL/6J) either exposed to 
normoxia (21% O2), chronic hypoxia (10% O2), or chronic hypoxia with subsequent re-
exposure to normoxia for 1, 3, 7, 14 days. Pulmonary vessels were laser-microdissected 
followed by RNA isolation and microarray analysis. In addition, the functional role of 
the candidate gene was confirmed in vitro in human primary PASMC and in vivo in 
respective knockout mice.   
In laser-microdissected murine pulmonary vessels, secreted protein acidic and rich in 
cysteine (SPARC) was identified as one gene consistently down-regulated in all re-
oxygenation time points investigated. Up-regulation of SPARC specifically in the 
pulmonary vasculature was observed in chronic hypoxic mice and in idiopathic 
pulmonary arterial hypertension patients. Furthermore, TGF-β1 or hypoxia-HIF-2α 
signaling pathway induced SPARC expression. In in vitro studies, SPARC silencing in 
primary human PASMC led to reduced proliferation and diminished PI3K/AKT/mTOR 
activation. However, SPARC in vivo knockout did not attenuate chronic hypoxia-
induced PH, possibly due to elevated AKT activation and PASMC proliferation under 
hypoxic conditions in SPARC knockout PASMC.  
In summary, SPARC was identified as a novel gene involved in dysregulation of 
primary human PASMC proliferation. Moreover, to the best to our knowledge this is 
the first evidence about its associated with the human PH disease.  
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 Abbreviations 
 
α-sma      Alpha smooth muscle actin 
ALK1      Activin receptor-like kinase 1 
AKT      Serin/Threonin Protein-Kinase Akt 
AMD-1     S-adenosylmethionine decarboxylase 1  
APS      Ammoniumpersulfat 
ATP      Adenosine triphosphate 
BCA      Bicinchoninic acid assay 
bFGF      Basic fibroblast growth factor 
B2M      β2-Microglobulin 
BM-40     Basement membrane protein-40  
BMPR2 Bone Morphogenetic protein receptor, type 
2 
Bp      Basepairs 
BSA      Bovines Serum-Albumin 
°C      Celsius 
CAV1      Caveolin-1  
cDNA      Complementary DNA 
cGMP      Cyclic guanosine monophosphate 
CI      Cardiac index  
CH      Chronic hypoxia 
CHD      Congenital heart disease  
ChIP      Chromatin immunoprecipitation  
CO      Cardiac output  
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CO2      Carbondioxide 
COPD      Chronic obstructive pulmonary disease  
CTEPH Chronic thromboembolic pulmonary 
hypertension 
d      Day  
DNA      Deoxyribonucleicacid 
dNTP      Deoxyribonucleotidtriphosphate 
DPBS      Dulbecco's phosphate-buffered saline 
EC      Endothelial cells  
ECM      Extracellular matrix components  
EDTA      Ethylenediaminetetraacetic acid  
EGF      Epidermal growth factor  
EF      Ejection fraction 
EMSA      Electrophoretic mobility shift assays  
ENG      Endoglin  
Erk1/2 Extracellular signal-regulated Kinases 1 
and 2 
ET-1      Endotelin 1 
FBS      Fetal bovine serum 
FDA      Food and Drug Administration 
FiO2      Fraction of inspired oxygen 
FOXO1     Forkhead box O1  
FP      Forward Primer 
FSTL1     Follistatin like protein 1 
g      Gram 
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GF      Growth factor 
h      Hours 
H      Hypoxia 
HCl      Hydrochloric acid 
HIF      Hypoxia-inducible factor 
HIF-1α     Hypoxia-inducible factor 1 alpha 
HIF-2α     Hypoxia-inducible factor 2 alpha 
HIV      Human immunodeficiency virus  
H2O      Water 
H2O2      Hydrogen peroxide 
hPASMC     human PASMC 
HPV      Hypoxic pulmonary vasoconstriction  
HR      Heart rate  
IgG      Immunoglobulin g 
ILD      Interstitial lung disease  
ILK      Integrin linked kinase  
IPAH      Idiopathic pulmonary hypertension 
JNK      c-Jun NH2-terminal kinase  
K+      Potassium 
kDa      Kilodalton 
kg      Kilogram 
KH2PO4     Monopotassium phosphate 
KCNK3 Potassium channel super family K 
member-3 
KLF4      Krüppel-like factor 4  
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KO      Knock out 
LV      Left ventricle 
µ      Micro (10-6) 
μg      Microgram 
μl      Microliter 
m      Mili (10-3) 
m2      Square meters 
M      Molar (Mol per Liter) 
MAPK     Mitogen-activated Protein-Kinase 
MCT      Monocrotaline 
Mdm2      Murine double minute 2  
mg      Milligram 
min      Minute 
mM      Milimolar 
mmHg      Milimeter mercury 
mPAP      Mean pulmonary arterial pressure  
mPASMC     Mouse PASMC  
MRI      Magnetic resonance imaging 
mRNA     Messenger RNA 
mTOR      The mammalian target of rapamycin 
mTORC1     mTOR complex 1  
mTORC2     mTOR complex 2  
n      Number of experiments 
N      Normoxia 
N2       Nitrogen 
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Na+      Sodium 
NaCl      Sodium chloride 
Na2HPO4     Disodium phosphate 
Na3VO4     Sodium ortho vanadate 
NC      Negative control 
NFATc2 Nfatc2      Nuclear factor of activated T-cells,  
cytoplasmic, calcineurin-dependent 2  
nm      Nanometer 
NO      Nitric Oxide 
O2      Oxygen 
OSA      Obstructive sleep apnea  
OPN      Osteopontin 
2-Propanol     Isopropylalcohol 
PAGE      Polyacrylamide gel electrophoresis 
PA      Pulmonary artery 
PAH      Pulmonary Arterial Hypertension 
PASMC     Pulmonary arterial smooth muscle cells 
PBGD      Porphobilinogen Deaminase 
PBS      Phosphate Buffered Saline  
PCNA      Proliferating Cell Nuclear Antigen 
PCR      Polymerase chain reaction  
PCH      Pulmonary capillary hemangiomatosis 
PDE-5      Phosphodiesterase 5  
PDGF      Platelet-derived growth factor  
PAEC      Pulmonary arterial endothelial cells 
  Abbreviations 
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PH      Pulmonary Hypertension 
PHD      Prolyl hydroxylase domain  
PI3K      Phosphatidylinositol 3-kinase  
pmol      Pikomol 
POPH      Portopulmonary hypertension  
PO2      Partial pressure of O2  
PPH      Primary pulmonary hypertension  
PPHN Persistent pulmonary hypertension of the 
newborn  
PPARG1 Peroxisome proliferator–activated receptor 
γ 1 
PVDF      Polyvinylidenfluoride 
PVOD      Pulmonary veno-occlusive disease 
PVR      Pulmonary vascular resistance  
RIPA      Radioimmunoprecipitation assay buffer  
ROCK      Rho-Kinase 
RP      Reverse Primer  
RNA      Ribonucleicacid 
rpm      rounds per minute  
RV      Right ventricle 
RVID      Right ventricular internal diameter  
RVF      Right ventricle failure  
RVH      Right ventricular hypertrophy  
RVP      Right ventricular pressure 
RVWT     Right ventricular wall thickness  
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s      Seconds 
SAP      Systemic arterial pressure 
Sch-PAH     Schistosomiasis-associated PAH  
SDS      Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-Polyacrylamide 
gel electrophoresis 
SERT      Serotonin receptor 
siRNA      small-interfering RNA  
SEM      Standard error of the mean  
SLUG      Snail family zinc finger 2  
SMA      Smooth muscle actin  
SMAD 9     Decapentaplegic 9 
SMC      Smooth muscle cells  
SMOC1 Secreted modular calcium binding protein 
1 
SMOC2 Secreted modular calcium binding protein 
2 
SOX‐5     SRY (sex‐determining region Y) ‐ box 5  
SPARC     Secreted protein acidic and rich in cysteine 
SPOCK1 SPOCK1     SPARC/osteonectin, CWCV, and Kazal- 
like domains proteoglycans 1 
STAT3 Signal transducers and activators of 
transcription 3  
SVR      Systemic vascular resistance  
Tab.      Table 
TAPSE     Tricuspid annular plane systolic excursion  
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TBE      TRIS-Borat-EDTA 
TBS-T      Tris Buffer Saline with 0,1% Tween20 
TEMED     Tetramethylethylenediamine 
TGFβ      Transforming growth factor beta  
TF      Transcription factors 
TRIS      Tris(hydroxymethyl)-aminomethane 
TSP1      Thrombospondin 1 
U      Unit 
q(RT)-PCR  Quantitative real-time polymerase chain 
reaction  
V      Voltage 
VEGF      Vascular endothelial growth factor  
VIP      Vasoactive Intestinal Peptide 
v/v      Volume per Volume 
vWF      von Willebrand factor  
Watt      Watt 
WB      Western Blot 
w/v      Weight per Volume 
WT      Wild-type 
5-HTT      5-Hydroxytryptamintran 
6MWD     6-minute walk distance  
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